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Abstract 
 
Metal-based compounds play a fundamental role in inorganic medicinal chemistry and the most 
important anticancer agents, approved worldwide as chemotherapeutic drugs, contain metals 
as the active component (i.e. platinum in cisplatin). Several examples of metal containing 
anticancer drugs are reported, including gold, ruthenium, silver, titanium, copper, cobalt. 
Surprisingly, Tellurium-based compounds never attracted the curiosity of the scientific 
community and tellurium chemistry with relevance to biological systems is poorly developed. 
Only recently, two Tellurium containing species have been investigated in clinical trials as 
anticancer agents, named AS101 (Ammonium trichloro(dioxoethylene-O,O’)tellurate) and Octa-
O-Bis-(R,R)-tartarate ditellurane (SAS)). These species, whose target are the cysteine residues of 
proteins (they act as cysteine protease inhibitors), are not stable in physiological conditions and 
decompose forming oxo-chloro tellurium(IV) compounds that are retained to be the real active 
species. Inspired by the results obtained with the above mentioned Te species, we developed a 
series of analogues of Te(IV)-based compounds with the aim to enhance the physiological 
stability in order to clarify the biological mechanism of action of these species. The coordination 
sphere of tellurium has been modified with different ligands, tuning the steric  electronic 
properties. The stability has been studied experimentally via multinuclear NMR spectroscopy 
(1H, 13C, 125Te NMR) in solution with accurate experiments in the presence of different 
equivalents of water. The experimental data have been combined with theoretical calculations 
that confirmed the stability trend. More than twenty new 
compounds have been synthesized and characterized with many spectroscopic techniques 
(multinuclear NMR (1H, 13C, 19F and 125Te-NMR), IR, Elem. Anal., Mass spectroscopy) including X-
ray structures. Reaction mechanisms for the formation of the new species have been proposed 
based on critical analyses of experimental and theoretical results. These species showed very 
high antibacterial potency, in particular against Gram negative E. Coli bacteria, with the activity 
produced by the hydrolysed product [TeOCl3]-. 
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1.1 Introduction 
 
1.1.1. The Biological role of metal ions 
 
Metal ions have a crucial role in living organisms and it has been estimated that there are 11 
common trace metal elements that make up 0.02 percent or around 8.6 g of the human body, 
including Iron, Copper, Zinc, Cobalt, Molybdenum and Vanadium. These elements have a 
tremendous influence on all biological functions in the body.1 Most of the trace metals are 
involved in vital biochemical reactions in organisms, both acting as catalysts for many enzymatic 
reactions and acting as centres for building stabilized structures such as proteins and enzymes.2  
It is known that a build-up or deficiency of these metals can lead to many human diseases.2  Trace 
metals are essential components of living cells and can be located in protein or enzyme catalytic 
sites and are involved in multiple biological processes ranging from catalytic site, electron 
exchanges to the biomolecules structural function.3  They are generally utilised in biological 
reactions.3  The elements iron, zinc and selenium for example are vital components in enzymes. 
Iron for example is involved in the binding, transporting and release of oxygen in humans.4 In 
humans proteins such as haemoglobin contain an iron atom that bind and carry oxygen in the 
bloodstream.  The active site of this protein contain a heme group where Fe(II) is bound (Figure 
1.1).4 
 
 
 
Figure 1.1.  Structure of a heme group with central Fe(II) atom and the structure of a heme group with 
oxygen bound to the Fe atom. 
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As mentioned, trace metals are essential components of cells and are frequently found in 
enzyme catalytic sites aiding cellular activities.  They are involved in multiple biological processes 
ranging from exchange of electrons to catalysis and also have a structural role in the protein or 
enzyme.3 Transition metals such as cobalt, zinc, manganese, silver, copper and vanadium are 
essential in the human body in small concentrations in order for catalytic biological reactions to 
occur.5  An example of a metal ion used in structural support of a protein is zinc, in a protein 
motif known as a zinc finger.  Zinc fingers (Figure 1.2) are small protein motifs that contain 
multiple finger like protrusions, in which zinc ions are coordinated with a combination of 
histidine and cysteines residues.  These zinc proteins are essential in DNA transcription 
processes.6 
 
Figure 1.2.  Structure of the repeating protein motif of a zinc finger, each zinc ion is coordinated to two 
cysteine and two histidine.  The purpose of each zinc ion is support and formation of the protruding finger 
like structure.  The grey dots are amino acids.6 
 
Trace metals are important in the human body, but there must be a fine balance between the 
cellular need and the concentration available in the human body, because excess metals can be 
toxic to the human body and can lead to many human diseases.  Some metals such as chromium, 
nickel, arsenic and cadmium, when present in excess, can lead to carcinogenesis and are 
therefore less advantageous for the body.5 Trace metals can also induce human diseases if there 
is a notable deficiency in the cells.  An example would be the cobalt found in the vitamin B12.  
Vitamin B12 was first isolated by Folkers and Smith in 1948 and is also known as cobalamin (Figure 
1.3). The structure of vitamin B12 is a highly functionalized tetrapyrrolic compound that contains 
three acetamides and four propionamides attached at the edges of the macrocycle corrin ring.  
The cobalt ion is coordinated to four nitrogen atoms of the corrin ring and two ligands situated 
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on both sides of the corrin ring.7 It is a known cofactor for enzymes that can catalyse a varied 
amount of biological reactions including methyltransfers, isomeration and dehalogenation.8 
 
 
Figure 1.3.  Structure of Vitamin B12 or cobalamin, involved in the catalysis of biological processes including 
methyltransfers, isomerisation and dehalogenation. 
 
 
Vitamin B12 or cobalamin, a vitamin that is water soluble that is said to have an important role in 
the metabolism process of all cells in the human body.  It is also a required component in DNA 
synthesis, and is involved in the metabolism of large biomolecules such as fatty acids and amino 
acids.8 Vitamin B12 has an intrinsic role in the production and synthesis of myelin, therefore has 
a major influence in the normal functioning of the human nervous system.  Deficiency in this 
vitamin can induce severe and irreversible damage to the brain and nervous system.8, 9 Many of 
these metals that are seen in trace amounts in the body have over the years been utilised as 
medicinal compounds to aid or cure human diseases.  Knowledge into the roles of metals in 
biological processes in the human body, are only being realised in the last 100 years but the 
therapeutic properties of metals are known throughout human history. 
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1.1.2. History of metals in medicine 
 
Throughout history, humans have understood the therapeutic properties of metals and have 
been using metals in medicines as far back as the earliest times of recordable human history.  
Early civilizations have been known or documented in utilizing metal-based compounds as 
therapeutic agents. As far back as 2500BC, Chinese realized the medical benefits of using gold.  
The ancient Egyptians used copper and zinc, copper as a way to sterilize their water and zinc 
being used in ointments to treat wounds.10  The famous Egyptian medical paper papyrus known 
as the Papyrus Ebers, dates from 1500BC and is said to be the first known written account of the 
use of metals in medicine, describing the use of copper to treat inflammation while iron was 
used to treat anaemia. While in 400 BC the Greek physician Hippocrates used mercury.11 In the 
16th century, the Swiss doctor and alchemist Paracelsus first pioneered the use of metals in 
compounds by using antimony, arsenic and mercury based salts for the prevention of certain 
human based diseases in medicine.12  During the early 17th century, the herbalist Nicholas 
Culpepper used a gold elixir called aurum potabile to treat diseases in the vital spirits which 
included melancholy, fainting, fevers and falling sickness.10 At the start of the 20th century, 
metals began to have an influence in modern day medicines.  Paul Ehrlich (1854–1915) 
discovered the arsenic organometallic drug Arsphenamine, named Salvarsan, which proved to 
be affective against syphilis.13 Arsphenamine was the 606th preparation to be tested in the 
laboratory of Ehrlich, hence when it first appeared it was known as number 606.  It was then 
marketed in 1910 under its trade name Salvarsan. The structure of which had been debated for 
many years but in 2005 with mass spectrometry, it was seen to be a mixture of two small arsenic 
three and five membered rings (Figure 1.4).14 
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Figure 1.4.  Structure of Salvarsan shows the two small arsenic molecules one a three membered ring 
structure and the other a five membered ring structure, the structure of Salvarsan was determined by 
mass spectrometry studies in 200514 
 
 
It was Ehrlich himself who first coined the words chemotherapy and magic bullet.13 Based on 
work from Robert Koch, gold compounds were used in the treatment of tuberculosis.  Koch 
found that compounds such as gold cyanide were extremely effective on cultures of 
Mycobacterium tuberculosis.  Even though after a number of investigations into gold salt 
compounds had shown to have no effects on experimental tuberculosis in guinea pigs, the 
proposition of utilizing gold compounds in chemotherapy was further indorsed by the work of 
Paul Ehrlich with arsenicals.15 In the 1920s Danish physicians who were desperate to find a 
remedy for tuberculosis, started implementing the treatment of gold sodium thiosulfate 
(Sanocrysin) (Figure 1.5).16 
 
 
Figure 1.5. Structure of Sanocrysin or gold sodium thiosulfate used in the mid 1920’s for the treatment of 
tuberculosis.16 
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In 1912, antimony based compounds were introduced for the treatment of leishmaniosis (Figure 
1.6).17  
 
 
Figure 1.6.  Structure of sodium stibogluconate used in the treatment of leishmaniosis. 
 
Over the years, trace transition metals have been mainly used as the therapeutic agents because 
they have a unique physical-chemical properties.18 
 
1.1.3 Transition metals in medicines 
 
The development of metal-based therapeutics have played an immense role in anti-tumor 
medicines. These metal ions, when administered into the body, can be used either for 
therapeutic or diagnostic purposes.19 The use of metal binding molecules (termed ligands 
derived from the Latin word “ligare”) can also remove metal ions from the body and are used 
for treatments in metal poisoning.19 These metal-based compounds can offer a greater versatility 
that is not often displayed by their rival organic or biological counterparts. For metal based 
compounds, ligand exchange reactions are possible within the cell or within the biological 
system, thus increasing the drugs potency and duration of its therapeutic effect.20 The various 
oxidation numbers displayed by the metal centre can encourage the generation of ROS (Reactive 
Oxygen Species) inside the cell enhancing the drugs therapeutic effect.21 Other properties that 
influence the activity of metal complexes are their coordination numbers, the electric charge it 
has and its hydrophilicity and lipophilicity.19, 21 The variables that account for the activity of 
metal-based drugs are great, therefore both in vitro and in vivo studies are indeed necessary to 
gain knowledge of their mode of action on pharmacological targets.22 Over the years, transition 
metal based drugs have shown to possess many benefits over the more popular organic based 
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products. This is due to the fact that they tend to offer a wide variety of coordinating numbers 
and geometries, usable redox states, tune-ability of ligand substitution thermodynamics and 
kinetics along with a vast range of structural diversity.23 Research in medicinal inorganic 
chemistry has flourished over the last number of years since the discovery of the platinum based 
metallopharmaceutical complex cisplatin over 50 years ago.24 There are currently several metal 
complexes in use for treatment of certain diseases.  Gold complexes have been utilised since 
1935 in the treatment of rheumatoid arthritis, starting in polymeric form and later on in the form 
of monomers such as auranofin (Figure 1.7).  At present auranofin is currently in use in both 
phase I and phase II clinical trials either alone or in combination therapy for the treatment of 
ovarian cancer.24 In addition to this, silver complexes such as silver sulfadiazine (Figure 1.6) and 
antimony (N-methylglucamine antimony) are being used as anti-infective agents. 
 
Figure 1.7.  Structures of gold compound Auranofin (left) and silver sulfadiazine (right). 
 
In addition to their therapeutic uses, metal based compounds also play a major role in 
radiological diagnostics and radiopharmaceuticals.  Barium X-ray examinations are used in 
radiology in the study of the gastrointestinal tract.25 In MRI (magnetic resonance imaging), the 
contrast agent Gadolinium exploits the paramagnetic characteristic of its +3 cation with seven 
unpaired electrons, which causes the rapid relaxation of water around the contrast agent, 
improving the accuracy of the MRI scan.  It is mainly used for detailed images of the 
cardiovascular system, organs and the brain.26  
In summary, metals show great versatility across a wide range of techniques in the medicinal 
chemistry field and over the years, numerous metal-based compounds have been designed 
which have shown therapeutic properties and toxicity. 
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1.1.4. Anti-cancer metal compounds 
 
Several metal-based drugs have been explored, in particular containing platinum, ruthenium, 
copper, cobalt, vanadium, titanium, gold and rhodium. In this section only some ruthenium and 
platinum anticancer drugs will be described. 
 
1.1.4.1. Platinum based anti-cancer complexes 
 
Currently, the most common classes of anti-cancer drugs being utilised in chemotherapy 
treatments are platinum-based compounds. It is known that 50 percent of all cancer patients 
undergoing chemotherapy are treated with the drugs cisplatin, oxaliplatin or carboplatin (Figure 
1.08).  Cisplatin is effective against testicular cancer with cure rates exceeding 95 %.27  Platinum 
drugs are also used on other cancers such as ovarian, bladder, non-small cell and small cell lung 
cancer, melanoma, lymphomas, myelomas, head and neck cancer and colon cancer.28  Cisplatin, 
oxaliplatin and carboplatin are square planar Pt(II) complexes that contain two inert ‘non leaving 
group’ ligands and two labile ‘leaving group’ ligands.  However, even though these drugs show 
great success, they have issues with cell resistance and toxicity, which has prompted new and 
improved therapies to be developed.28  
The mechanism of action of all three platinum complexes combines the cellular uptake, the 
aquation/activation step, DNA platination and cellular processing that eventually leads to 
apoptosis. 29 
 
Figure 1.08.  Platinum based anticancer compounds approved by FDA: cisplatin (left), carboplatin (centre) 
and oxaliplatin (right).28 
 
Cisplatin was first synthesised in 1844 by M. Peyrone, while its chemical structure was only 
determined in 1893 by Alfred Werner.  It did not gain any scientific relevance until 1965 when 
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Barnett Rosenberg a physicist at Michigan State University discovered that platinum electrodes 
after electrolysis formed compounds had the ability to inhibit cell division in Escherichia coli.30 
This platinum-based compound was identified as cis-dichlorodiammineplatinum(II) or cisplatin. 
Since its discovery of its chemotherapy properties, has given rise to a greater interest into the 
use of other coordination complexes of platinum, palladium and other noble metals in the 
treatment of cancer.29, 31 The study of the effect of cisplatin on tumor cells was further carried 
out on two murine models of tumors, sarcoma 180 and leukaemia L1210.  In vivo studies showed 
that among all proposed platinum complexes the most efficient and least toxic was that of 
cisplatin.29, 31 The FDA approved cisplatin in 1978 for clinical use as an antineoplastic agent and 
since then it has become one of the most used drugs in chemotherapy. Cisplatin is recognised as 
one of the most effective anticancer drugs available on the market today and is included on the 
list of essential medicines by the World Health Organisations.  Cisplatin is active and clinically 
proven in the fight against various types of cancers including sarcomas, cancers of soft tissue, 
muscles, bones and blood vessels.29 During clinical trials problems with cisplatin arose regarding 
the toxicity of the compound as well as cell resistance against the compound.28  To compensate 
this cisplatin and other cancer drugs such as 5-fluorouracil, methotrexate and paclitaxel has been 
trialled with success as part of a combination therapy to try and reduce cell resistance.32 
Cisplatin is a square planar Pt(II) complex, consisting of two chlorides and two ammonia in cis 
position with respect to the central platinum +2.28 Although it is still not fully known how 
cisplatin’s uptake and efflux to and from the cell occurs, studies have shown that there are three 
possible routes of drug entry into the cell.  The first is said to be passive diffusion through the 
transmembrane channels.  The second type of transport is by protein carriers such as OTCs 
(organic cation transporters which are involved in the transport of endogenous cations, these 
are OCT1 and OCT2).33 The third involves the use of protein carriers such as CTR1 (copper 
transporter 1, Figure 1.09).  Studies have shown that mutation of this protein CTR1 increases 
cisplatin resistance and reduction of platinum levels in the cell.  The efflux from the cell is 
mediated by two ATPases, ATP7A and ATP7B and by MRP (multidrug resistance Protein)27, 34 The 
MRP family of proteins contains at least six members, MRP1 and five of its homologues, these 
are membrane proteins which in turn belong to the ABC superfamily (ATP binding cassette).35 
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Figure 1.09. Schematic depiction of cisplatin uptake through passive diffusion, CTR1 transporter proteins, 
the aquation of the molecule in the cell cytoplasm to the entry of the cell nucleus and binding to DNA and 
efflux via ATPase ATP7B27. 
 
Cisplatin undergoes hydrolysis after it crosses the cell membrane, due to a drop of chloride  
concentration, leading to the formation of the monoaquo-species [Pt(NH3)2Cl(OH2)]+ and the 
diaquo-species [Pt(NH3)2(OH2)2]2+  that act as acid forming a mixture of water soluble hydroxides, 
hydroxyl-complexes and even dimers (Figure 1.10)36. 
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Figure 1.10. Schematic showing the equilibrium of cisplatin hydrolysis and the formation of hydrated 
complexes in aqueous solution.37 
 
The aqueous species that is formed from this process are considered to be the reactive forms of 
cisplatin, being very electrophilic in nature and possessing excellent leaving groups react readily 
with nucleophilic species.  The main target of cisplatin is DNA, with the target groups usually the 
secondary or tertiary nitrogen bases especially the purine ones (adenine and guanine) due to the 
nucleophilicity of the imidazole portion.  The guanine bases that are situated in the major groove 
of DNA are sterically exposed and therefore are accessible to cisplatin and a covalent bond is 
therefore formed at position N7 (Figure 1.11).27 
 
Figure 1.11. Cisplatin – DNA interaction, Figure shows the cisplatin binding to DNA forming both 1,2 
intrastrand and 1,3 intrastrands. Also shows a guanine residue with N7 binding site for the Pt(II) complex. 
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Cisplatin forms 1,3 intrastrand and 1,2 interstrand crosslinks between both DNA strands inducing 
a variety of cellular responses such as transcription inhibition, replication arrest, cell cycle arrest 
which in turn leads to necrosis and apoptosis.29 The main adducts formed between DNA and 
cisplatin are shown in Figure 1.12.36 
 
Figure 1.12. Covalent bonds formed with activated cisplatin molecule and DNA.  The major DNA lesions 
are intrastrand DNA adducts and interstrand crosslinks.36 
 
 
Cisplatin over the years has been used as the sole chemotherapy agent, but has also been seen 
that the complex is highly toxic on the patient with side effects that include fever, 
myelosuppression (condition where bone marrow activity is reduced), hyposthenia, nausea and 
vomiting, nephrotoxicity (kidney damage)38 and neurotoxicity.34 Although cisplatin treated 
cancer patients show high responsiveness towards the drug, some patients will relapse 
eventually with cisplatin resistance cancers.  Cisplatin resistance mechanism is caused by 
changes in the cellular uptake of cisplatin and efflux of cisplatin from the cell, increased 
detoxification of the drug, inhibition of the apoptosis cycle and increased DNA repair see Figure 
1.13.39 Cisplatin resistance has prompted research into 2nd and third generation platinum drugs,  
Carboplatin being the second generation (used to treat in particular ovarian cancer) and 
oxaliplatin the third generation platinum drug (used to treat colorectal cancer, one of the most 
cisplatin resistant cancer).27,30 
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Figure 1.13.  Shows the proposed mechanism of cellular resistance of the drug cisplatin.  Increased efflux 
from the cell, decreased uptake of the drug into the cell and increased DNA repair, increased 
detoxification, inhibition of apoptosis and increases in platinum-DNA adduct bypassing all lead to cisplatin 
tumor resistance.39 
 
1.1.4.2 Ruthenium-based Anticancer Agents 
 
Ruthenium complexes are thought to be less harmful than platinum based agents and are 
thought to fragment DNA.  Ruthenium(III) is considered to be a bio reductive metal which suits 
treatment of highly reductive tumor tissue over normal healthy tissue with ruthenium(III) 
becoming ruthenium (II). Ruthenium drugs are designed to mimic platinum based drugs for 
targeting DNA.40 The toxicity of ruthenium drugs are less than those of platinum based drugs and 
the reactivity of Ru(II) complexes are greater than those of Ru(III) complexes.  The non-toxic Ru 
(III) can be administered as a prodrug, at pH 7 the drug is inactive.  The pH of cancer cells is lower 
than that of normal cells and when the Ru(III) enters the cell the complex is reduced to the active 
Ru(II) complex. It is thought that reduction occurs either inside the cell, by mitochondrial 
proteins or microsomal single electron transfer proteins or by trans-membrane electron 
transport systems which are situated outside the cell, which means that for the drug to be 
effective against cancer cells it does not require entry into the cell.41 42 One such ruthenium(III) 
drug is NAMI-A which has undergone clinical trials and has been found to have a different mode 
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of action relative to the platinum complex cisplatin.  It is not cytotoxic but has anti-proliferative 
activity.41 
 
Figure 1.14. Structure of Ruthenium NAMI complex (left) and of NKP1339 (right).43 
 
Another ruthenium based complex NKP1339, trans-[tetrachloridobis (1H-indazole) ruthenate(III) 
(Figure 1.14) has also had clinical trials and is found to active in solid tumors.  The mechanism of 
action is thought to be via binding to serum proteins such as albumin which then accumulates in 
the endoplasmic reticulum of the cell.  Since tumors have poor lymphatic drainage the 
accumulations of albumin in the tissue is detected and apoptosis is triggered. Under hypoxic 
conditions this Ru(III) complex is thought to generate ROS , which leads to  protein damage and 
subsequent endoplasmic reticulum response that leads to cell death.44 
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1.1.4.3 Cobalt-based anticancer agents 
 
Cobalt(III) complexes have been studied as potential carriers of drugs to the hypoxic 
environment of cells.  Cobalt(III) can be reduced to cobalt(II) in a reductive tumor environment 
in some cases releasing the toxic active ligand to kill the cancer cells.45  
Figure 1.15. Structure of cobalt bis(thiosemicarbazone) complex.46 
 
Cobalt bis (thiosemicarbazone) complex (Figure 1.15) is a cobalt(III) complex which becomes 
cobalt (II) in hypoxic environments leading to the loss of its ligands “L” which have been shown 
to be cytotoxic. The reduction to cobalt(II) produces a labile d7 complex, which facilitates the 
removal of ligands within its coordination sphere.  Therefore, these kind of complexes can 
perform as chaperones to selectively deliver cytotoxic ligands to hypoxic environments where 
metal reduction is favoured.46 
 
1.1.4.4. Copper Anticancer based complexes 
 
Copper is a common metal in the human body, serving as a cofactor for certain enzymatic 
reactions such as Cu/Zn-superoxide dismutase, cytochrome c oxidase, thyrosinase, 
ceruloplasmin and other proteins that are involved in respiration, iron transport, metabolism 
and cell growth.47  Copper exists outside the body mainly as Cu(II) and when complexed it favours 
square planar, square pyramidal or distorted octahedral geometry due to its d9 configuration 
and Jahn-Teller effect.  Cu(II) prefers nitrogen and oxygen ligands and is capable of coordinating 
4-6 ligands to the metal centre.  Copper complexes are ideal alternatives to metal based 
complexes due to their range in oxidation states and coordination ability.48 
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The role of copper in cancer is not straightforward as copper is thought to aid in the generation 
of new blood vessels, through the activation of epidermal growth factor which promotes cancer 
cell survival.  It is also increase the formation of ROS, has an involvement in necrotic cell death 
and is involved in the upregulation of Bax that can induce apoptosis.49 The study of copper 
complexes has been undertaken since cisplatin was introduced as a chemotherapy drug.  Various 
copper(II) complexes were found to be cytotoxic, with NSAIDs or Schiff bases being the most 
common ligands.  These Cu(II) complexes display catalytic activity against ROS and may cause 
DNA strand breakages.50 The copper complex of 1,10-phenanthroline (Figure 1.16) has been 
studied for its chemical nuclease activity. Over the years there has been many Cu-complexes 
synthesised and reported as cytotoxic agents which have shown anticancer activities in both 
vitro and in vivo tests. The dichloro(1,10-phenanthroline)copper(II) complex showed to 
oxidatively degrade DNA and RNA by attacking the sugar group.51, 52 The clinical activities of 
complexes of 1,10-phenanthroline have shown great potential with antiturmoural, 
antimycobacterial, antifungal and antimicrobial activities.53-55 
 
 
Figure 1.16.  Structure of the anticancer complex dichloro(1,10-phenanthroline)copper(II) 
 
1.1.5. Chalcogens 
 
The elements found in group 16 of the periodic table are classed as chalogens.56  The word 
chalcogens derived from the Greek word khalkόs, which means copper, and the Latinized Greek 
work genes, meaning born or produced. This group of elements are also referred to be members 
of the oxygen family.  They comprise of the elements oxygen (O), sulphur (S), selenium (Se), 
tellurium (Te) and the radioactive element polonium (Po). 
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Sulphur has been known since before the Middle Ages and in the 18th century oxygen was first 
discovered as an element. The elements selenium, tellurium and polonium were all discovered 
in the 19th century, while livermorium was discovered as late as 2000. All elements in the 
chalcogens family have six valence electrons and so are two electrons short of a full outer shell.  
They have oxidation states ranging from -2, +2, +4 and +6.  They have relatively low atomic radii, 
especially the lighter ones.56 Lighter chalcogens are typically non-toxic in their elemental form, 
and they are very often critical to life and are involved in most biological activities. However, the 
larger or heavier chalcogens are normally more toxic to an organism.  Chalcogens are involved 
in many biological processes, either it being a nutrient or a toxin.  The lighter ones such as oxygen 
and sulphur are rarely toxic and are usually helpful in their pure form and are the building blocks 
for many proteins and enzymes.  Selenium is an important nutrient but can be toxic in high 
concentrations.  Tellurium has unpleasant effects (micro-organisms however can utilize it) and 
polonium is extremely harmful due to its chemical toxicity and its radioactivity properties. 
Tellurium lies in the diagonal that identify the metalloids, together with Boron (B), Silicon (Si), 
Germanium (Ge), Arsenic (As) and Antimony (Sb). These metalloid elements show properties of 
both metals and non-metals and are referred to as semi-metals.  One of the properties 
metalloids have is they act like non-metals when reacting with a metal and act like metals when 
reacting with non-metals.57 Some physical-chemical properties of chalcogens are listed in Table 
1.1. 
 
Table1.1. Selected properties of elements in group 16 of the periodic table.58, 59 
Property Oxygen Sulfur Selenium Tellurium Polonium 
Atomic symbol O S Se  Te  Po  
Atomic Mass (amu) 16 32.07 78.96 127.6 209 
Atomic number 8 16 34 52 84 
Atomic radii (pm) 48 88 103 123 135 
Density (g/cm3) at 25oC 1.31 (g/L) 2.07 4.81 6.24 9.2 
Electron affinity 
(kJ/mol) -141 -200 -195 -190 -180 
Electronegativity 3.4 2.6 2.6 2.1 2 
First ionization energy 
(kJ/mol) 1314 1000 941 869 812 
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Ionic radii (pm) 140 (-2)  
184 (-2), 
29 (+6) 
198 (-2), 42 
(+6) 
221 (-2), 56 
(+6) 
230 (-2), 97 
(+4) 
Melting point/ boiling 
point (oC) 
(- 219/-
183) 115/445 221/685 450/988 254/962 
Normal oxidation states -2 
(-2), (+4), 
(+6) 
(-2), (+4), 
(+6) (-2), (+4), (+6) (-2), (+4) 
Reaction with Oxygen   SO2 SeO2 TeO2 PoO2 
Reaction with 
Hydrogen H2O H2S H2Se None None 
Reaction with Nitrogen NO, NO2 None None None None 
Reaction with X2 (where 
X2 is halogen) O2F2 
SF6, S2Cl2, 
S2Br2 SeF6, SeX4 TeF6, TeX4 
PoF4, PoCl2, 
PoBr2 
Valence electron 
configuration 2s22p4 3s23p4 4s24p4 5s25p4 6s26p4 
 
1.1.6. Tellurium 
 
Tellurium was first discovered in 1782, by the chemist Franz-Joseph Mueller von Reichenstein 
(1742 – 1825) while studying gold containing ores. The name Tellurium is derived from the Latin 
word tellus, meaning Earth. It’s abundance in the earth’s crust is 0.027 ppm which is similar to 
that of silver, however since its discovery back in 1782, tellurium chemistry was mostly ignored 
in the biochemical field and it has only started in recent years.60 Tellurium can be found naturally 
in two elemental forms, one of them a metallic silver in form whilst the other is brownish black 
in form. Tellurium exhibits some spectroscopic properties that are ideal for the characterization 
of tellurium compounds. Tellurium found in its natural form contains a mixture of several 
different isotopes, 120Te (natural abundance 0.09%), 122Te (2.55%), 123Te (0.89%), 124Te (4.74%), 
125Te (7.07%), 126Te (18.84%), 128Te (31.74%) and 130Te (34.08%).60 
Metalloid complexes have been noted to have particular biological effects on cells and tissues 
and their particular therapeutic potential have been studied for the last number of years.61. 
Since its discovery in 1782, tellurium has been considered to be of little significance in normal 
daily life.  There are some exceptions, however, such as the ever-increasing presence of CdTe 
particles in photochemical devices present in solar panels and photovoltaic systems (Figure 
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1.17).62 For years, tellurium has been considered toxic and therefore its various inorganic, 
complex and organic compounds have been ignored until recently in medicine, toxicity, and 
pharmacology and drug development. It is however surprising the disinterest in tellurium in life 
sciences is considering the variety of tellurium chemistry.  
 
 
Figure 1.17. Presence of Tellurium in daily life.63 
 
Tellurium chemistry gives rise to a rich array of inorganic and organic compounds, including 
inorganic salts (for example tellurides Te2-, tellurites TeO32-, and tellurates TeO42-), inorganic 
complexes and a vast variety of organotellurium compounds (Figure 1.18).  Many of these 
compounds have been found to be stable. Tellurium and its many compounds are reactive and 
interact freely with biomolecules, including cysteine- and selenocysteine- proteins and enzymes.  
The selective inhibition by tellurium compounds of certain main enzymes can be essential in 
future therapeutic interventions. Even though tellurium is a non-essential trace element, it does 
not mean that its applications are limited in terms of drug design but can be as effective as those 
complexes of gold and platinum.63 
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Figure 1.18. Range of tellurium chemistry from its in-organic compounds, complexes and organotellurium 
compounds. All three types of tellurium complexes have been of interest recently for their biological 
activities.81,82 
 
In particular, some tellurium(IV) complexes have shown excellent anticancer properties and have 
been the subject of many research papers over the last years. It has been found that by 
inactivating cysteine proteases in the human body, specific Te(IV) complexes influence thiol 
redox biological activity. The mechanism of action of these Te(IV) complexes consists on the 
formation of Te(IV) – thiol chemical bond or a disulfide bond in a specific protein which in turn 
leads to a conformational change in the activity site of the protein which possibly results in the 
loss of that proteins biological activity.61  
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Figure 1.19.  Tellurium is metabolism.  Some micro-organisms can reduce tellurium salts to the non-toxic 
Te(0) or elemental form while humans after ingesting tellurium can excrete it through their lungs or urine 
following methylation.63 
 
Tellurium is not required in living organisms and does not have any benefit to life and so is 
regarded as non-essential trace element in nature.  Even though tellurium is not required for any 
organism’s survival, many organisms are still able to utilise tellurium and have the ability to 
excrete many forms of tellurium in its methylated form (Figure 1.19).63 The method of tellurium 
metabolism varies between different organisms, but it follows the same metabolic pathways 
which are used in the metabolism of selenium and sulfur.63  
Studies have shown that microorganisms can exist in environments that contain tellurium salts 
and have developed high toxicity resistance against tellurium.  Many of these organisms 
overtime have evolved to form a bio-reductive approach in coping with tellurium and also 
enhancing their ability to remove tellurium by generating elemental tellurium.  Some of these 
microorganisms have the ability to survive in environments that are rich in tellurate and tellurite 
and have adapted in a way as to cause the reduction of these tellurium compounds to a less toxic 
form, in this case elemental tellurium Te.64  Also in oxygen depleted environments, reduction of 
these anions to metallic Te allows some of these organisms to support anaerobic growth by 
enabling respiration by using these salts or anions as electron acceptors as a substitute for 
oxygen.  These organisms that can utilise tellurate and tellurite are rare and three such bacteria 
have been identified as Bacillus selenitireducens, Sufurospirillum barnesii and Bacillus 
beveridgei.64  These three bacteria have been isolated from deep ocean hydrothermal vent 
worms by Csotonyi and Baesman et al.65, 66 When these bacteria were grown with tellurate or 
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tellurite as terminal electron acceptors they produced uniformly sized nanoparticles of 
elemental Te, such as nanorods of 10nm x 200nm in size for Bacillus selenitireducens and 
irregular spheres less than 50nm by Sufurospirillum barnesii.65, 66 
In certain organisms reduction of tellurium salts continues further to H2Te which is then 
converted through methylation to (CH3)2Te or to ionic (CH3)3Te+ and in these two states can be 
excreted by the organism.  Certain fungi can produce (CH3)2Te which can be toxic, but because 
of its volatility can be easy removed.67 Biovolatization plays a key role in removal of tellurium 
from the fungi but also from the environment that the fungi resides in.  The tellurium species 
H2Te, (CH3)2Te and (CH3)3Te+ are not the only tellurium compounds that can created by living 
organisms.  It has been known that in cases of low or no sulfur sources some fungi, if in the 
presence of Na2TeO3, can produce tellurium containing amino acids such as tellurocysteine, and 
telluromethionine.67 It is not understood if these tellurium amino acids play any biochemical role 
in these fungi but fact that they are present tells that: (1) Tellurium may not be as foreign to 
biochemistry as once thought but is in fact metabolised by various microorganisms which 
possess the ability to utilize these tellurium compounds;  (2) in harsh environments such as sulfur 
depletion, tellurium can breach the void and be exchanged for sulfur in some biomolecules.  
Therefore, tellurium can be considered as having an essential role in biochemistry, even if it is 
due to deprivation of sulfur for these organisms to exist. 
Tellurium compounds in nature have high reactivity and selectivity towards sulfur and selenium 
biomolecules.  These interactions often occur in the form of redox reactions.  Tellurium based 
compounds such as tellurides (RTeR), telluroxides (RTe(O)R), tellurols (RTeH) and ditellurides 
(RTeTeR) are redox-active and the oxidation states range from -2 to +6.68  Tellurium shows a high 
affinity to other chalcogens such as oxygen, sulfur and selenium.68 The reactive oxygen species 
(ROS), such as H2O2 has the ability to oxidise telluroxides and tellurols to ditellurides with the 
peroxide acting as an electrophile.  Thiols on the other hand readily behave as reducing agents 
for tellurium agents, and in doing so transform telluroxides to tellurides and ditellurides to 
tellurols and in this instance the nucleophile is the thiol.68 
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Most tellurium compounds display glutathione peroxidase (GPx)-like activity and when 
glutathione (GSH) is present can catalyse H2O2 reduction (Figure 1.20).  Organotellurides were 
studied by Kumar et al and have shown to be chain breaking antioxidants whose biochemical 
activities resemble vitamin E.  These vitamin E mimics can reduce peroxyl radicals with greater 
efficiency than α-tocopherol and in the presence of thiol reducing compounds are capable of 
decomposing hydroperoxides.69 
Figure 1.20.  Reduction of H2O2 in the presence of glutathione with a tellurium catalyst. 
 
Tellurium agents interact with proteins and enzymes that contain cysteine residues in a way that 
can be detrimental to the proteins and enzymes activity by interfering with the ‘cellular thiolstat’ 
eventually leading to cell death via apoptotic pathways.70 In vivo studies with tellurite on rats 
and mice show that ingestion of TeO32- cause inhibition of squalene epoxidase which results in 
transient demyelination of peripheral nerves caused by the binding of methyl-tellurium 
complexes to the thiol groups of vicinal cysteine residues that are situated in the active site.71 
Toxicity studies of organotellurium compounds were also studied by Nogueira on mice and rats 
and found that the toxic effects of these compounds coincide with interactions between the 
tellurium and the thiol groups of the cysteine.72  
As mentioned earlier tellurium has a high affinity to sulfur compounds and therefore certain 
biological effects are associated with this tellurium-sulfur chemistry.  However tellurium has also 
a high affinity to selenium, therefore some selenium containing targets may include enzymes 
such as selenoprotein P and also various GPx enzymes.73 Tellurium compounds can also effect 
the activity of the human selenoenzyme thioredoxin reductase (TrxR) due to selenium-tellurium 
interactions.  Tellurium interactions with antioxidant selenium type proteins and enzymes may 
indirectly bring about oxidative stress rather than acting as antioxidants.  The effects of these 
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interactions with these proteins and enzymes can result in problems ranging from severe liver 
damage to impairment and quite possibly hippocampal and prefrontal cortex neuron damage.74 
 
1.1.6.1. Oxidative stress on cancer cells versus non cancer cells 
 
Reactive Oxygen Species (ROS) are all chemically reactive species which all contain oxygen.  The 
ROS species include the free radicals such as superoxide anion (O2•-) and the hydroxyl (OH•) 
radical.  They are also made up of non-radical oxygen forms, which include hydrogen peroxide 
(H2O2) or nitroperoxide (ONOOH).  These ROS species are constantly being produced by 
eukaryotic cells during aerobic cellular metabolism.75  These ROS species play a key role in 
signaling pathways in response to intra- and extra-cellular changes.  They are also removed from 
the cell by the anti-oxidant systems that are located inside the cell.  The redox status of a cell is 
a function of the relative concentrations of both the oxidized and reduced forms of ROS, 
proteins, enzymes, RNS (reactive nitrogen species, thiol containing molecules and other cellular 
factors.76 In a normal cell there is a balance between the generation and elimination of ROS 
species, and under normal physiological conditions there is an equilibrium between the these 
ROS species and the antioxidants. Oxidative stress occurs when this equilibrium is changed by 
an increase in ROS species which lead to damage of the cellular macromolecules.77 
Cancer cells are cells that exhibit uncontrolled growth that potentially metastasize leading to 
lethal malignancy. For these cells to continue to undergo cell division and proliferation, these 
cells must adapt their metabolic processes to promote their survival.78  Even though the 
mechanisms of cellular transformation during carcinogenesis in different cancer cells can occur 
in variety of cellular pathways, the metabolic requirements of all these cells are generally 
similar.79  It is seen that cancer cells have increased metabolic rates and therefore have increased 
ROS formation which leads to an increased oxidized environment. Therefore, these cells must 
adapt their antioxidant scavenging pathways to evade ROS induced death.  To achieve this 
cancer cells must up-regulate their antioxidant scavenging molecules such as glutathione 
peroxidase (GPx), glutathione-S-transferase (GST), glutaredoxin (Grx), thioredoxin (Trx), 
superoxide dismutase (SOD) and catalase (CAT).78, 79 Several of these antioxidants rely on the 
reducing properties of NADPH, which is found to be induced in cancer cells and is seen as a key 
metabolite of the pentose phosphate pathway, to help maintain their activity to removed ROS 
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and repair any ROS induced damage.  This therefore leaves cancer cells with little or no room to 
adapt future ROS induction and so if the ROS system is altered slightly it would result in oxidative 
stress dependent cell death.78-80 In normal healthy cells, ROS occurs in steady levels and so are 
easily removed from the cell thus preventing cellular damage.  If however, there does occur an 
elevated level of ROS in a healthy cell, these cells can counteract these increased ROS levels by 
induction of the antioxidant system.78, 81 
The fact that cancer cells have such small room to adapt to any extra ROS induced damage it 
makes them more susceptible to oxidative stress than non-cancer cells.  Therefore, the induction 
of oxidative stress can be achieved by using redox modulators such as Tellurium compounds.  
These redox modulating compounds can provide an interesting therapeutic window and has 
been seen as a promising avenue in anti-cancer therapy.82  Tellurium compounds have shown 
higher selectivity and sensitivity in cancer cells and can induce oxidative stress on these cells 
which result in cell apoptosis. The pro-oxidant properties of these Te compounds, that are 
responsible for their cytotoxicity and anti-cancer activity are mainly down to ROS generation and 
oxidation of thiol containing proteins. 
 
1.1.6.2. Antimicrobial properties of Tellurium compounds 
 
Throughout human history bacteria has been the main causes of infectious diseases and in 
particular the Gram-negative pathogens Escherichia coli (E.Coli),and Enterobacter cloacae 
(E.Cloacae). Most foods consumed daily can harbor the bacterial strain E.Coli which when 
consumed can lead to illness.  These Gram-negative pathogens are treated with antibiotics, 
however over the years these pathogens have built up a resistance to these antibiotics which 
has in recent years become a concern to world health organisations.83   This resistance to 
antibiotics has made the fight against disease causing bacteria much more difficult.  It is 
therefore important to find new drug compounds that can combat these bacterial strains. 
E.Cloacae is a member of the Enterobacteriaceae bacteria family.  These bacteria are responsible 
for infectious diseases and is treated with antibiotics such as gentamicin or tobramycin.  
However, these two antibiotics are seen to be very toxic, in particular to people who suffer renal 
failure.84 Therefore, over the last few years there has been advances in research and 
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development into alternative drug compounds that are both non toxic and effective against 
antibiotic resistant bacteria. 
One such drug is tellurium AS101, which has shown antibacterial properties against bacteria K. 
pneumonia, E. Cloacae and has been investigated for its antimicrobial effects against the bacteria 
Aeromonas salmonicida.85 AS101 has been shown to be non-toxic in various cell cultures as well 
as in vivo models.  It is presently undergoing phase II clinical trials for the treatment of psoriasis 
and atopic dermatitis.86  It therefore appears that AS101 maybe a potential substitute or 
supplement to antibiotic treatments.  The mechanism of action of AS101 against Gram-negative 
bacteria indicates that the molecule can penetrate the cells of the bacteria through the outer 
membrane.  The purpose of this outer membrane on bacterial cell walls is to serve as a 
permeability barrier, preventing entry of toxic compounds while allowing the influx of nutrient 
molecules through porins.87, 88  Porins are pore forming proteins found on the cells outer 
membrane.  The porins on the outer membrane of Gram-negative bacteria are large enough to 
allow AS101 (MW 312Da) to penetrate the cell.86  AS101 enters the bacteria via the bacterium 
porins which leads to swelling and eventually to cell death. 
Another tellurium compound that has shown antimicrobial activity is tellurium SAS.  This 
molecule has shown strong antimicrobial action against E. Coli.85 Investigations into the 
compounds mechanism of action against this bacteria has determined that it is different from 
that of AS101.  In AS101, the molecule penetrates through the outer membrane of the cell via 
the protein porins, SAS is too large to enter through the porins so it is assumed that the molecule 
penetrates through the lipid layer of the outer membrane.89  When SAS enters the cell 
membrane it causes damage to the Na+/K pumps that are located in the inner membrane.  This 
damage causes a leakage of ions through the damaged membrane.   The leakage of phosphorus 
ions indicates loss of phosphorus containing molecules such as ATP and other nucleotides from 
the cell.  These cells cannot multiply under these conditions; therefore the bacteria growth is 
inhibited. 
These two tellurium compounds have shown interesting activity against antibiotic resistant 
strains of bacteria and therefore these and other future tellurium compounds can be utilized in 
the fight against present and future bacterial induced diseases. 
 
Introduction                                                                                                                                   Chapter 1 
 
28 
 
1.1.6.3. Anticancer properties of Tellurium compounds 
 
Tellurium occurs in both inorganic and organometallic complexes. Some of these compounds 
have been studied and have shown to express specific biological activities.90 Alkali metal 
tellurites and tellurates show activity in microbiology, organotellurides and diorganoditellurides 
have potent antioxidant activity, while inorganic and organic tellurium compounds are potent 
inhibitors of caspase and cathepsin proteases.90  Caspases are a family of protease enzymes that 
have crucial importance in programmed cell death which include apoptosis, pyroptosis, 
necroptosis as well as inflammation.91, 92  Caspases get their name due to their specific cysteine 
protease activity, in that a cysteine residue located in the active site which nucleophillically 
attacks and cleaves a target protein only after an aspartic acid residue.91 It is estimated that up  
to 11 or 12 confirmed and named caspases in humans are involved in  various cellular functions.91  
Cathepsins B, L and D are lysosomal cysteine and aspartic proteases which are found in almost 
all mammalian cells. The main function of cathepsins is protein recycling within the lysosome 
and are said to be involved in a variety of other physiological, as well as pathological processes, 
which include maturation of the MHC class II complex, bone remodelling, tumor progression and 
metastasis, rheumatoid arthritis and osteoarthritis.  Overexpression and secretion of cathepsins 
induces invasion and metastasis of tumor cells (Figure 1.21).93 
 
 
 
Figure 1.21.  Imbalance between cathepsins and cysteine protease inhibitors (CPIs) in tumor cells.  
Overexpression and secretion of cathepsins induce the invasion and metastasis of tumor cells99 
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At present two inorganic tellurium(IV) compounds have been studied for their anti-cancer 
properties and their mechanism of action.  These compounds are trichloro(dioxoethylene-
O,O’)tellurate or AS101 and Octa-O-Bis-(R,R)-tartarate ditellurane (SAS) (Figure 1.22). 
 
 
Figure 1.22. Structure of: left, tellurium(IV) compound AS101 (Ammonium trichloro(dioxoethylene-
O,O’)tellurate) and, right,  Octa-O-Bis-(R,R)-tartarate ditellurane (SAS). 
 
Over the last few years, AS101 has been the most studied synthetic tellurium compound with 
respect to its biological activity.  AS101 is a potent immunomodulatory agent both in vitro and 
in vivo and has shown a variety of potential therapeutic applications. It has been trialled in phase 
I and phase II clinical studies with cancer patients.100  The biological activities primarily results 
from the specificity of Te(IV) redox-modulating activities which enable inactivation of certain 
cysteine proteases such as cathepsin B, inhibition of specific tumor survival proteins such as 
survivin, or the obstruction of tumor IL-10 production.94 IL-10 or interleukin-10 is an anti-
inflammatory cytokine and is also known as human cytokine synthesis inhibitory factor (CSIF).95  
Most or all of these properties have direct influence on anti-cancer activity or sensitization of 
tumors to chemotherapy.  Along with these properties, inorganic Te(IV) compounds show 
excellent safety profiles which means that both tellurium complexes SAS and AS101 have a 
promising future in anti-cancer therapy.94  
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1.1.6.4. Ammonium trichloro(dioxoethylene-O,O’)tellurate (AS101) 
 
Ammonium trichloro(dioxoethylene-O,O’)tellurate (AS101, Figure 1.22) is an inorganic 
ammonium tellurate with high affinity to thiols which gives it its therapeutic property against 
certain cysteine proteases. The mechanism of action of AS101 relates to its ability to react with 
thiols of cysteine residues and catalyzing their oxidation.96  AS101 is a small tellurium(IV) 
compound that has already undergone phase II clinical trials in cancer patients,97 is a potent 
immunomodulatory both in vitro and in vivo and shows a variety of potential therapeutic 
applications.96, 98  
Over the years, all the gathered information suggests that the biological activity of AS101 is 
related directly to the specific tellurium-cysteine chemical interactions.  The Te(IV)-thiol bond 
may lead to conformational changes or disulfide bond formation in specific proteins or enzymes 
which in turn lead to that protein or enzyme losing its biological activity.99, 100  It has been 
reported that the AS101 molecule specifically cause the inactivation of cysteine proteases yet 
exhibit no effect on other families of serine, aspartic and metalloproteases based upon their 
unique Te(IV)-thiol chemistry.  This inactivation of cysteine proteases can be reversed by 
reducing agents such as NaBH4, which supports the claims that inactivation of these cysteine 
proteases involves the oxidation of the catalytic thiol to a disulfide (Figure 1.23).101, 102 
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Figure 1.23. (A) Formation of disulfide from two thiol molecules; (B) Structure of cysteine amino acids 
containing S-S bridge; (C)  Cysteine residues on a protein sequence with internal disulfide bridges. Disulfide 
bridges are important in proteins as they can maintain correct 3D structure its overall function within the 
biological system. 
 
The thiol-Te interaction of AS101 inhibits activity of specific integrins by redox modulation.  
Integrins are transmembrane proteins receptors that facilitate cell extracellular matrix (ECM) 
adhesion.  When chemically bound to a specific ligand, integrins can initiate signal transduction 
pathways that mediate cellular signals.  Integrins are made up of two subunits, α and β and their 
combination has its own specific binding and signaling properties.103  The development of cancer 
depends on the blood supply. Angiogenesis, the process of forming new blood vessels involves 
the migration, growth and differentiation of endothelial cells, is regulated through the activation 
of integrins including α1β1, α2β1, α6β1, αvβ3, and αvβ5 that are expressed on the surface of 
endothelial cells.104, 105 The interactions between thiols and AS101 enables the inhibition of the 
integrin αvβ3 on endothelial cells. In solid tumors, the cancer cells express various growth factors 
that allows cells to escape from body’s immune surveillance.  IL-10 (Interleukin 10) which is an 
anti-inflammatory cytokine95 is secreted spontaneously from a variety of human cancer cells 
which include ovarian carcinoma, melanoma, lymphoma, neuroblastoma, renal cell carcinoma, 
colon carcinoma, glioma and non-small cell lung cancer.106-109 Patients found with various solid 
and hematopoietic tumors are seen to have elevated levels of IL-10.110 In preclinical and clinical 
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studies of AS101, the activities of AS101 showed the molecules ability to cause the direct 
inhibition of the anti-inflammatory cytokine IL-10 and at the same time showed an increase in 
specific cytokine levels.96, 111 These immunomodulatory properties were seen to be a crucial 
factor for clinical trials of AS101. Inhibition of the IL-10 by AS101 results in the de-
phosphorylation of Stat3 (Signal transducer and activator of transcription 3) which is then 
followed by the reduced expression of Bcl-2 shown in Figure 1.24. These activities of AS101 are 
associated also to its ability to sensitize tumor cells to other chemotherapeutic drugs that results 
in increased apoptosis.  AS101 was sensitizing the human aggression tumor GBM to paclitaxel 
(Taxol) in vivo and in vitro by IL-10 inhibition. Inhibition of IL-10 by AS101 due to Te(IV)-thiol 
interaction, result in the functional inhibition of integrin activity which give rise to a reduced 
expression of pAkt ( which is a combination of proteins PI3K (phosphatidylinositol 3-kinase) and 
Akt (Protein Kinase B) that in turn leads to the decrease in pGSK3β (which is a multifunctional 
serine/threonine kinase found in all eukaryotes)112 expression and in IL-10 production.113 
 
Figure 1.24.  Protein expression pathway cascade when AS101 interact with integrin.  The decrease in the 
IL-10 expression results in a decrease in pStat3 which in turn lowers expression of survivin increasing cell 
death, decreasing angiogenesis and metastases.118 
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Tellurium compounds have been ignored by research biologist in the past, because their 
instability in aqueous/physiological conditions. AS101 compound in an aqueous environment 
hydrolyses, forming [TeOCl3]- which is understood to be the active part of the compound (Figure 
1.25).114 
 
 
 
 
Figure 1.25.  (A) Interaction between AS101 and cysteine and seleno-cysteine and related mechanism of 
action. (B) Hydrolytic cleavage of AS101 with the displacement of the diol ligand and formation of the real 
reactive component [Te(IV)OCl3]−.115 
 
AS101 is an effective inhibitor of cysteine proteases and has shown several protective 
therapeutic applications in vivo preclinical and clinical studies.96, 98, 116, 117  Tellurium(IV) 
compounds have the ability to inhibit integrin functions such as adhesion, migration and 
metalloproteinase secretion mediation in murine melanoma cells B16F10.  AS101 in particular, 
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can stimulate the proliferation of normal lymphoid cells producing lymphokines that are said to 
regulate lymphopoiesis and myelopoiesis.96 AS101 has also shown strong antibacterial activity 
against Gram-negative bacteria such as the Enterobacter cloacae and also Klebsiella 
pneumoniae, which is an opportunistic pathogen and is one of the more common Gram-negative 
pathogens that is said to cause pneumonia, urinary tract infections and also sepsis in patients 
that suffer with low immunity.123,118, 119 AS101 enters the bacteria via the bacterium porins which 
leads to swelling and eventually to cell death.120, 121 AS101 activity against Gram-negative 
pathogens shows great promise in the fight against infectious diseases due to the increase in 
antibiotic resistant pathogens worldwide. 
 
1.1.6.5. Octa-O-bis-(R,R)-tartarate ditellurane (SAS) 
 
Octa-O-bis-(R,R)-tartarate ditellurane (SAS, Figure 1.20) is a relatively new Te(IV) compound.  It 
comprises of two Tellurium atoms bound to four oxygen atoms of two carboxylates and two 
alkoxide of two tartaric acids residues. Studies have shown that SAS is highly stable in aqueous 
solutions compared to many other Te(IV) compounds.122 Te(IV) complexes such as TeX4 and 
Te(OR)4 interact with nucleophiles such as alcohols, carboxylates and thiols to form Te(Nu)4 
products and SAS interacts with thiols forming unstable Te(SR)4 products.122, 123 The mechanism 
of action of SAS is different from AS101 and the interactions cysteine thiols leads to the reduction 
of tellurium to Te(0) and the oxidation of the thiol functional group to a disulfide.122,124 SAS is 
non-toxic to mice even after months of continuous treatment and the biological activity its 
activity is directly related to its specific chemical interactions with cysteine thiol residues.  These 
interactions lead to conformational changes or disulfide bond formation in a specific protein or 
enzyme that will result in the inhibition of biological activity for that particular protein or 
enzyme.125, 126 The molecule SAS has shown antibacterial activities against Gram-negative 
bacteria such as E coli.  The transport of the molecule into the bacteria was studied and found 
to be different from that of AS101. In AS101, the transport of the molecule occurs via the pore 
forming proteins or porins that are located on the outer membrane of the bacteria, while the 
larger SAS molecule in internalized by passive diffusion (Figure 1.24).85 
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Figure 1.26. Scanning electron microscope image of the bacteria E-Coli. Screen shots (a) and (c) are of 
untreated cultures while (b) and (d) show SAS treated cultures, the arrows indicate holes in the bacteria’s 
cell wall.85 
 
1.2. Project Aim 
 
The aim of this research project is to develop, starting from the already known Te(IV) compounds 
AS101 and SAS, new inorganic Te(IV) compounds with increased physiological stability and 
antibacterial/anticancer activity.  AS101 is currently undergoing phase I and phase II clinical trials 
for cancer and treatment, and have shown less toxicity compared to other metal-based drugs.  
Chapter two regards the syntheses, characterization and antibacterial studies of a series of new 
analogues of AS101. One of two vicinal carbon of the diol ligands in AS101 was modified with 
different alkylic chain, tuning the steric and electronic properties. The new compounds were 
fully characterized (1H, 13C and 125Te-NMR, IR, mass and Elemental Analyses) and the effect of 
the substituents in the aqueous stability of the new compounds was investigated. Theoretical 
calculations, in collaboration with Dr. Barbara Fresch (Chemistry Department, Padua University, 
Italy), allowed to identify the hydrolytic cleavage mechanism and confirmed the stability results 
obtain experimentally via NMR studies. Antimicrobial activity was investigated in collaboration 
with Dr. Kevin Kavanagh of the Department of Biology in Maynooth University. This work has 
been published in Journal of Inorganic Biochemistry: “Stability of antibacterial Te(IV) 
compounds: A combined experimental and computational study”, Kenneth D’Arcy, Alan Doyle, 
Kevin Kavanagh, Barbara Fresch, Diego Montagner, J. Inorg. Biochem. 2019. 
Due to interesting results obtained in chapter 2, in chapter 3 the effect of the substitution of 
both vicinal carbon of the diol ligand was investigated. Several new diol ligand were reacted with 
TeCl4 in a similar manner of chapter 2, but completely new and different species were obtained. 
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In particular, with the use of pinacol, 1,1,2,2 tetramethyl-1,2 ethanediol, completely new species 
were formed. Some of them have also been characterized by X-ray crystallography, multinuclear 
NMR and IR spectroscopies. These new species are salts where the cationic part is an oxazoline 
derivative formed by the activation of the nitrile solvent with pinacol and the anion is a [TeCl6]2- 
moiety. TeCl4 act as a catalyst and the effect of different nitriles (acetonitrile, benzonitrile, 
fluoroacetonitrile) in the formation of analogues species have been investigated. The stability of 
these species in aqueous environment was studied via NMR in a similar way as in chapter 2 and 
the role of the cation and of the [TeCl6]2- was determined.  
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2.1. Introduction 
 
Tellurium is a metalloid element with several available oxidation states going from -2 to +6.1 
Tellurides of formula M2Te are compounds formed by Te(-II) and noble elements such as Au or 
Ag that are highly unstable and in the presence of oxygen are oxidized to tellurite [Te(IV)O3]2-. 
The biological properties of tellurium are poorly characterized, but it is known that some bacteria 
and fungi are able to uptake Te as amino acids, replacing the Sulfur atom and forming Tellurium-
cysteine and Tellurium methionine.2, 3 The oxidation state +4 is the most stable and interesting 
from biological application, with multiple complexes of organo-tellurium(IV), containing a direct 
Te-C bond , reported. These complexes are stable in aqueous solution and seem to have a 
promising and potential role in protease inhibition and integrin inactivation.4-8 Besides these 
families of organo-tellurium complexes, Albeck and co-workers ultimately developed two 
“inorganic” tellurate Te(IV) compounds, named AS-101 and SAS whose structure is depicted in 
Figure 2.1. These complexes are effective inhibitors of cysteine protease and showed several 
protective therapeutic applications and in vivo, preclinical and clinical studies have been 
conducted.3, 6, 9-16 
 
Figure 2.1. Structure of the “inorganic” Te(IV) compounds AS-101 and SAS 
Te(IV) compounds can inhibit integrin functions such as adhesion, migration and 
metalloproteinase secretion mediation in B16F10 murine melanoma cells. AS-101 in particular, 
can stimulate the proliferation of normal lymphoid cells producing lymphokines that are 
regulators of lymphopoiesis and myelopoiesis.9 AS-101 also showed strong antibacterial activity 
in particular on Gram-negative bacterium Enterobacter cloacae.17 Recently, Albeck and Cunha, 
reported that AS-101 is not stable in physiological conditions and is subjected to hydrolysis 
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where the diol ligand is displaced with the formation of [Te(IV)OCl3]-, which is likely the bioactive 
species in biological investigation (Figure 2.2).18, 19 Due to the promising activity of AS-101 in term 
of anticancer and immune-modulating properties, the aim of the study presented in this chapter 
was to design, synthesize and characterize a series of AS-101 analogues with different ligands, 
in order to investigate their stability properties in aqueous environment and ultimately found a 
tellurate Te(IV) complex stable enough to perform biological studies in physiological conditions. 
Figure 2.2. Hydrolysis of tellurium AS101 complex in aqueous solution forming the active species 
[Te(IV)OCl3]-, after diol ligand is displaced. 
The ethylene glycol of AS-101 has been substituted with a series of diols with increasing alkyl 
chain length and electron withdrawing groups, producing eight novel Te(IV) complexes with 
formula NH4[(RC2H3O2)Cl3Te] (where R =H (201); CH3 (202); CH2CH3 (203); CH2CH2CH3 (204); 
CH2CH2CH2CH3 (205); CH2CH2CH2CH2CH2CH3 (206); CH2Cl (207); Ph. (208)). The aqueous stability 
has been evaluated using 1H, 13C and 125Te NMR and theoretical studies allowed an 
understanding of the molecular basis of the observed trend. The modelling of the reaction 
mechanism suggests that a longer alkyl chain substituent enhances the stability of the complex 
by interfering with the formation of water clusters necessary for mediating the proton transfer 
steps involved in the hydrolysis of the Te-O bonds. The antimicrobial activity was evaluated in 
vitro on Escherichia coli and other bacteria strains. 
 
 
 
 
AS-101, [ammonium trichloro (diol-O,O′)tellurate] derivatives                                                             Chapter 2 
 
45 
 
2.2. Results and discussion  
2.2.1. Synthesis and characterisation  
A series of eight complexes, which are the analogues of the AS101 compound, which has the 
formula NH4[(RC2H3O2)Cl3Te] (where R = H (201); CH3 (202); CH2CH3 (203); CH2CH2CH3 (204); 
CH2CH2CH2CH3 (205); CH2CH2CH2CH2CH2CH3 (206); CH2Cl (207); Ph. (208)), have been synthesized 
in the laboratory as described in the synthesis and characterization section and in scheme 2.1 
below.  In short, TeCl4 and the correspondent diol were stirred in dry acetonitrile and mixtures  
refluxed at 80oC for intervals ranging from 4 to 120 hours.  All solids formed were extracted by 
filtration after the CH3CN solution was concentrated by rotary evaporation or by the addition of 
Et2O. 
 
Scheme 2.1. Synthesis of the complexes, where R =H (201); CH3 (202); CH2CH3 (203); CH2CH2CH3 (204); 
CH2CH2CH2CH3 (205); CH2CH2CH2CH2CH2CH3 (206); CH2Cl (207); Ph (208). 
These complexes can also be synthesized using the microwave as previously observed for the 
AS101 compound, thus reducing reaction times on all compounds from several hours to 
40mins.20, 21  The reaction mechanism for all complexes involves four steps as described by Sredni 
et al and is shown below in scheme 2.2.22 
 
Scheme 2.2.  The mechanism of reaction of the AS101 compound involves four steps shown, all complexes 
formed of the AS101 analogue are assumed to be formed this way. 
All the compounds synthesised were characterised by elemental analysis, IR spectroscopy, Mass 
spectrometry, 1H, 13C, and 125Te NMR (all the spectra are reported at the end of this chapter in 
the supporting information Figures 2.14-2.20).   
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All the complexes show a unique 125Te NMR peak in DMSO-d6 around 1680 ppm, the typical 
region for these kind of species 23, 24 and in the IR spectra is clearly visible the stretching of the 
ammonium counter cation at 3200 cm−1 (all IR spectra are reported at end of this chapter Figures 
2.22-2.27). A detailed IR study in the range 4000–200 cm−1 was performed for 
compounds 201 and 203. Further insights into the coordination sphere of tellurium can be 
obtained by comparison with the IR spectra of the starting ethylene glycol, whose vibrations 
have been fully assigned previously25. For instance, in the mid-IR spectrum of 
compound 201 (Figure 2.3) the bands associated with the –COH moieties of the diol 
(ν(OH) = 3400, δip(COH) = 1424, δoop(COH) = 644 cm−1) have disappeared, consistent with the 
coordination of the deprotonated glycol to the Te(IV) center.  
 
Figure 2.3. Mid IR spectra of (A) compound 201 and (B) free ethylene glycol. 
 
The C-O stretching vibrations were detected at lower energy, in agreement with values reported 
for analogous derivatives11. New bands were recorded at 3234 (νa(NH4+)) and 1408 (δa(NH4+)) 
cm−1 accounting for the presence of the ammonium counterion26. In the far-IR region (Figure 
2.4), the spectrum of compound 201 appears dramatically different from that of ethylene glycol, 
the latter showing only one weak broad band at 520 cm−1 assigned to the δ(CCO)25. In line with 
the results reported by Albeck et al.,11 in the solid state the complex should present a distorted 
square-pyramidal geometry in which the two oxygen atoms of the deprotonated diol occupy the 
axial and one equatorial positions.  
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Figure 2.4. Far IR spectra of (A) compound 201 and (B) free ethylene glycol 
 
Accordingly, two tellurium-oxygen stretching vibrations are foreseeable, ν(Te-Oax) and ν(Te-Oeq), 
the former expected at higher frequency26. For 201, Te-O vibrations were assigned to two new 
bands recorded at 607 and 528 cm−1, respectively. Such assignments, together with the two 
intense bands observed at 467 and 406 cm−1 assigned to the overall deformation of the Te(O2C2)-
ring, are fully consistent with those reported for analogous derivatives27. According to the very 
few relevant papers published to date, tellurium-chloride derivatives exhibit Te-Cl stretching 
vibrations in the range 400–200 cm−1, such as 378/312 (TeCl4)28, 220–250 ([TeCl6]2−)29, 30, 286/263 
(Ph2TeCl2)31 and 271/221 ([Te(dioxoethylene-O,O′)Cl3], Raman) cm−1 32. In the present study, two 
new intense bands were recorded at 351 and 298 cm−1, which can be reasonably assigned to the 
antisymmetric and symmetric stretching involving the -TeCl3 moiety. The IR spectra of 
derivative 202 resemble closely those of 201. The same pattern of bands was observed in the 
far-IR region, whereas in the 4000–600 cm−1 range the only minor differences would be 
attributed to the new vibrations involving the CH3CH2CH- pendant, such as those recorded at 
3048 (ν(CH)), 2967/2872 (νas(CH3)), 1354 (δs(CH3)) and 776 (ρ(CH3)) cm−1 32. The complexes are 
very stable in pure CH3CN or DMSO solution, but they decompose upon addition of H2O, as 
previously described by Albeck and co-workers16. The hydrolysis reaction releases the free diol 
with the formation of trichloro-tellurium(IV) oxide [TeOCl3]−, as shown in Figure 2.5. 
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Figure 2.5. Hydrolysis reaction of Te(IV) complexes 
 
The displacement of the ligand is followed by 1H, 13C and 125Te NMR (Figure 2.6 for 203): the 
signals of the coordinated and of the released diols appear shifted in the NMR spectra, and this 
effect is particularly remarked in the 13C NMR for the two carbons bound to the two donor 
oxygen of the diols (Figure. 2.6 center for compound 203 and Figures 2.28–2.32 at end of 
chapter). 
 
Figure 2.6. 1H (left), 13C (center) and 125Te (right) NMR of: A) 203 (0.5 mM in DMSO-d6); B) 203 + 10 μL D2O 
(10 eq.); C) 203 + 20 μL D2O (20 eq.); D) 203 + 30 μL D2O (30 eq.); E) free ligand. 
 
After addition of 10, 20 and 30 equivalents of water, the free diol is displaced with the formation 
of NH4[TeOCl3], visible in the 125Te NMR at δ 1560 ppm (Figure 2.6 right). To confirm the nature 
of the decomposed product, 20 mg of compound 203 were dissolved in 1 mL of CH3CN and 5 mL 
of H2O and, after 2 h, the solution was dried under vacuum. The white solid obtained was washed 
with cold CH3CN, H2O and diethyl ether and further dried under high vacuum pressure. Mass 
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spectrometry (Figure 2.7), peak at (−) m/z 250.81 corresponding to [Cl3OTe]−) and Elem. Analysis 
confirm the nature of the product as NH4[Cl3OTe] (Elem. Anal. %H (1.50), %N (5.23); found H 
(1.91), N (5.04)). 
 
Figure 2.7. ESI-Mass spectra (-) of the decomposed product [TeOCl3]- 
 
Analyzing the integrals of the released ligand vs the integrals of the starting compound with 
respect the equivalents of water, it is possible to estimate on the stability of the complexes. 
The data show that there was an evident direct proportion between the alkyl chain of the diol 
and the stability of the Te complexes; an increase of the chain length corresponds to an increase 
of the stability, with complex 206 more stable than 205, 204, 203, 202 and 201 (Figure 2.8). 
After addition of 30 eq. of water, compound 201 is almost completely decomposed while 206 is 
more resistant (55% not decomposed). Complex 207 with a Cl electro-withdrawing substituent 
is the least stable (it completely decomposes upon addition of 20 eq. of H2O) while, 
unfortunately, it was not possible to evaluate the stability of complex 208, since it was not 
obtained pure. 
 
Figure 2.8. Decomposition of complexes 201-206 with addition of water. Left, marked line representation; 
right, 2D column representation. 10 equiv D2O, 20 equiv D2O and 30 equiv D2O 
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2.2.2. Theoretical Investigation  
To gain a molecular understanding of the factors affecting the stability of the complexes we 
modelled at the quantum mechanical level complex 201 and complex 205, representing the 
limiting case of short and long alkyl-chain substituent, respectively, and complex 207 with the 
chloro-methyl substituent. The optimized equilibrium geometries and the analysis of the 
electronic structures in terms of atomic charges33, 34 are reported in Figure 2.9. 
 
Figure 2.9. Optimized equilibrium geometries of complex 201 (left) and complex 205 (right) in implicit 
DMSO. The complexes are anions with charge -1 and singlet spin multiplicity. The colour code is Te in 
orange, Cl in green, O in red, C in grey and H in white. The atomic charge from Natural Population Analysis 
are reported for each atom (as fraction of the elementary electronic charge |e|) and the main distances 
are given in Angstrom (Å). 
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Both atomic charges and structural parameters of the Te center are not significantly affected by 
the change in the alkyl chain length nor by the chlorination of the substituent, it can therefore 
be inferred that the source of the complexes ‘slightly different stability’ does not arise from the 
different strengths of the Te-O bonds. As it also emerges from the stability studies, the solvating 
environment plays a central role in establishing the equilibrium of the decomposition reaction 
of the complexes. Computationally, there are several approaches to treat solvation and we will 
use two of them in the following to elucidate the energetics of the complex decomposition. In 
the first approach (implicit solvation), the solvent is treated as a continuous, uniform dielectric 
medium characterized by its dielectric constant Ɛ. The solute molecules are placed inside an 
empty cavity within the dielectric medium and the interactions between solvent and solute 
consists primarily of electrostatic interactions, that is the mutual polarization of the solute and 
the solvent. We use the Solvation Model based on Density (SMD) which was found to perform 
well for predicting reaction energies in solution35. The reaction free energy, ΔGr, obtained for the 
decomposition of the three complexes, 201, 205 and 207, by considering the free energy of 
reactants and products implicitly solvated in acetonitrile, DMSO and water are reported in table 
2.1, together with the free energy of the same reactions in gas-phase. Positive values of free 
energy of reactions reflect a stable complex which does not undergo significant decomposition. 
Table 2.1. Free energy of the decomposition reaction of compounds 201, 205 and 207. The table reports 
the gas-phase energy and the set of energies calculated with an implicit solvent model of acetonitrile, 
dimethyl sulfoxide (DMSO) and water. The reaction considered in gas-phase and in implicit solvent was 
[(RC2H3O2)Cl3Te]− + H2O = [RC2H3(OH)2] + [Cl3OTe]− where reactants and products were considered as non-
interacting molecules each species was solvated separately. The second set of energies are calculated by 
explicit consideration of a hydration shell composed of five water molecules. The labels R1, R2 and R3 
refers to three different conformers of the hydrated reactant differing by the positions of the water 
molecules, see Figures 2.10 and 2.11 for the structures of reactants and products. 
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From the analysis of the values of the reaction free energy in implicit solvent we can draw two 
main conclusions.  
● We do see consistent trend in how the relative gas-phase stability of the three complexes is 
changed by solvation. Complex 205 is less prone to decomposition than complex 201 in all the 
considered solvents and complex 207 is the most destabilized by solvation. This can be 
understood by considering the solvation energies of the different species involved in the 
reactions (see Table 2.2) which show that the chloro-methyl substituted glycol is considerably 
more stabilized by solvation than the corresponding reactant complex. 
Table 2.2. Solvation free energies of isolated reactants and products of the complex decomposition 
reaction for Complexes 201, 205 and 207. The free energy of solvation is calculated as the difference 
between the free energy of the gas-phase and the free energy of the solvated ground state geometries. 
The label R indicates the complexes (reactant) and P the free substituted glycol resulting from the 
decomposition reaction. A water molecule which reacts with the complexes has a solvation energy of -6.8 
kcal/mol in Acetonitrile, -6.3 kcal/mol in DMSO and -12.0 kcal/mol in water. The Tellurium(IV) oxide 
[OCl3Te]- has a solvation energy of -52.6 kcal/mol in Acetonitrile, -52.3 kcal/mol in DMSO and - 55.6 
kcal/mol in water. 
 
A word of caution must be given since the calculated difference in the reaction free energies 
between complex 201 and 205 (ΔΔGr of about 1–1.3 kcal/mol) is small and falls within the error 
of the numerical method. On the other hand, such a small difference is consistent with the 
experimental results which report a decomposition of 0.8% for 201 and 0.4% for 205 in the case 
of 10 eq. of water (Figure 2.8), corresponding to a difference in the reaction free energies of the 
two complexes of about 2 kcal/mol.  
● Because of the active involvement of water molecules in the decomposition reaction, the 
implicit solvent calculations fail to predict the spontaneous decomposition of the reactants in 
water. Indeed, the use of a cavity model assumes that the solute electron density is not changed 
by specific interactions with individual solvent molecules and the reaction does not itself involve 
specific solvent molecules. The limitations resulting from these assumptions can be addressed 
AS-101, [ammonium trichloro (diol-O,O′)tellurate] derivatives                                                             Chapter 2 
 
53 
 
by including explicit solvent molecules inside the cavity. We introduce an explicit micro-solvation 
environment by considering the complexes interacting with five water molecules (see the 
reactants in Figure 2.8). The solute and its hydration shell are then considered solvated in DMSO 
with the implicit model to better reproduce the experimental condition of the NMR experiments. 
Multiple equilibrium geometries of reactants and products were generated. We reported in 
Figures 2.10 and 2.11 the structures of the three lower lying energy structures of the hydrated 
complex and the most stable structure of the products resulting from the decomposition of 
compound 201, 205 and 207.  
  
Figure 2.10. Optimized equilibrium geometries of complex 201 (upper row), 205 (central row) and complex 
207 (bottom row) hydrated with five water molecules. The structures are optimized in implicit DMSO, they 
have an overall negative charge and a singlet spin multiplicity. The leftmost geometries are the most 
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stable, the other conformers have relative energies of +3.1 kcal/mol and +3.8 kcal/mol for complex 201 
and +1.9 kcal/mol and 3.3 kcal/mol for complex 205. and +7.5 kcal/mol and +9.2 kcal/mol for 207. 
  
Figure 2.11. Optimized equilibrium geometries of the products of the decomposition reaction of complex 
201 (left) and complex 205 (middle) and complex 207 (right). The structures include four water molecules 
and they are optimized in implicit DMSO. Structures have an overall negative charge and a singlet spin 
multiplicity. 
The reaction free energies are reported in (table 2.1) for the different conformers of the 
reactants R1–R3 (Figure 2.11). We recover the spontaneous decomposition of the complexes 
and an increased stability of the complex substituted with the longer alkyl chain in good 
agreement with the experimental findings. By defining the solvation contribution to the free 
energy of reaction as the difference between the ΔGr calculated with the explicit micro-solvation 
shell model and its gas-phase value we find that these contributions are −27.3 kcal/mol, 
−18.2 kcal/mol and −12.6 kcal/mol for complex 207, complex 201 and complex 205, 
respectively. These results suggest that the trend in the stability of the complexes increasing 
with the length of the alkyl chain results from a less efficient hydration of the structure of the 
reactants relative to the decomposition products. Indeed, the mechanism of the decomposition 
reaction involves multiple steps of proton transfer requiring the active involvement of clusters 
of water molecules. Mechanistic insights into the decomposition reaction are shown in Figure 
2.12 and they were obtained by investigating the reaction path starting from the most stable 
structure of the hydrated compound 201 (Reactant in Figure 2.12).  
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Figure 2.12. Mechanistic insights into the decomposition reaction of 201 by considering an explicit micro-
solvation shell formed by 5 molecules of water. The free energy of the structures relative to the reactant 
complex is reported in parenthesis (in unit of kcal/mol). Geometries corresponding to black lines are 
minima of the potential energy surface while TS1 is a transition state with an imaginary frequency of 
131 cm−1. The vertical line in the middle of the picture divides the hydrolysis of the fist Te-O bond from 
the hydrolysis of the second Te-O bond which leads to the formation of the free glycol. 
 
Structures with real frequencies corresponds to minima of the potential energy surface that are 
equilibrium geometries of reactants, products and reaction intermediates. Geometries of 
transition states correspond to a saddle point of the Potential Energy Surface (PES) and are 
characterized by an imaginary frequency for the mode identifying the reaction coordinate. The 
mechanism of the decomposition reaction was assumed to consist of two subsequent hydrolysis 
steps. We identify a transition state (TS1 in Figure 2.12) corresponding to the rupture of the first 
Te-O bond at a free energy of +17.2 kcal/mol from the reactant complex. Breaking this bond 
requires both a nucleophilic attack of a water molecule to the Te center together with a proton 
transfer from the water to the forming glycol molecule. Following the intrinsic reaction 
coordinate corresponding to the imaginary frequency of TS1 we find a reaction intermediate 
where a -OH group is coordinated to the Te center at an angle of about 120° from the plane of 
the -TeCl3 moiety (H1a in Figure 2.12). This structure can rearrange in other conformers 
(H1b and H1c in Figure 2.12) where the most stable (+1.7 kcal/mol from the reactant) is 
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characterized by the -OH group coordinated to Te in equatorial position. The hydrolysis of the 
second Te-O bond to form the free glycol molecules again requires the coordination of a second 
water molecule to the Te centre. This second nucleophilic attack to the Te centre comes most 
probably from the side opposite to the Te-O bond to break (see structure preH2 in Figure 2.12). 
This geometry implies that the water molecule attacking the Te centre transfers its protons to 
other acceptors and the protonation of the glycol is operated by a separate species (which might 
be a second water molecule or even a H3O+ ion). Most probably there are many possible paths 
for these multiple proton transfer steps and the mechanistic details depends on the relative 
position of the hydrating water molecules. The increasing of the decomposition ratio with the 
numbers of water equivalents observed experimentally is readily explained by considering that 
clusters formed by a higher number of water molecules are more efficient in mediating proton 
transfer steps trough the more extended H-bond network. From the intermediate structure 
where two -OH groups are coordinated to the Te centre (H2 in Figure 2.12) a further proton 
transfer step leads to the formation of the trichloro Tellurium(IV) oxide 
[OCl3Te]− (Products in Figure 2.12) where one of the vertexes of the square pyramid is occupied 
by a coordinated water molecule, at least in solution. In the mass spectrum of the decomposed 
product, as described before, the coordinated water molecule is not visible due to the ESI 
conditions. 
 
2.2.3. Antimicrobial Activity 
Since AS-101 and Te(IV) species showed antimicrobial activity against Enterobacter cloacae and 
Pseudomonas aeruginosa, some of the complexes synthesized, (203, 204 and 205), together with 
the free ligands, were selected and screened for antimicrobial activity against the most common 
and representative bacteria, including Escherichia coli (Gram negative), Staphylococcus aureus 
(Gram positive), methicillin resistant Staphylococcus aureus (MRSA), Pseudomonas aeruginosa, 
and the yeast Candida albicans (fungi representative). These compounds showed interesting 
activity against the Gram negative bacterium E. coli (MIC50 values between 15 and 20 μM as 
reported in Table 2.3) while they were less active or inactive against the other bacteria and C. 
albicans. The free diol ligands that are displaced in physiological conditions, have been analyzed 
and they do not show any activity. We conclude that the similar activity of the complexes is 
probably due to the hydrolyzed product [Cl3OTe]−. Interesting, a black metallic, granular layer 
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was visible in the assay medium of E. coli treated plates and it is probably due to the reduction 
of the Te(IV) by the bacteria, as already observed by Yang and co-workers (Figure 2.13)39. 
 
Table 2.3. MIC50 and MIC80 values for compounds 203-205 against E-Coli 
 
 
 
 
 
Figure 2.13. Black precipitate observed at the bottom of the plate of E. coli treated with 203. 
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2.3. Experimental 
2.3.1 Material and methods 
TeCl4 and all the diol ligands have been purchased from Sigma-Aldrich or TCI Europe. All solvents 
were used without further purification except for CH3CN which was kept dry over molecular 
sieves under inert atmosphere. All NMR spectra were recorded on a Bruker Advance 
spectrometer with the probe at 293 K, operating at 500 MHz for the 1H, at 125 MHz for the 13C 
and at 158 MHz for the 125Te nucleus, respectively. Spectra were recorded in DMSO-d6 using 
Me4Si as the internal standard for 1H and 13C while diphenyl ditelluride was used as external 
reference for 125Te. All chemical shifts δ are reported in ppm. FT-IR spectra were recorded 
(compounds 201 and 203) from either CsI disks (solid samples) or KRS-5 thallium bromoiodide 
cells (neat liquid samples) at r.t on a Perkin Elmer Frontier FT-IR/FIR spectrophotometer in the 
range 4000–600 cm−1 (32 scans, resolution 4 cm−1) and in the range 600–200 cm−1 (32 scans, 
resolution 2 cm−1). Data processing was carried out using OMNIC version 5.1 (Nicolet Instrument 
Corporation). For all the other compounds Infrared (IR) spectra were recorded in the region 
4000–400 cm−1 on a Perkin Elmer ATR (Attenuated Total Reflectance) precisely spectrum 100 
FT/IR spectrometer. Elemental analysis (carbon, hydrogen and nitrogen) were performed with a 
PerkinElmer 2400 series II analyzer. ESI (Electro Spray Ionization) mass spectra were recorded in 
negative mode with a Waters LCT Premier XE Spectrometer. The stability of the complexes has 
been evaluated following the decomposition reaction by 1H, 13C and 125Te NMR. Each compound 
was accurately weighted and dissolved in 400 μL of DMSO-d6 to obtain 125 mM solution 
(0.05 mmoles). 10 μL of D2O were added in three consecutive aliquots and the NMR spectra were 
recorded 1 h after each addition (each addition corresponds to 10 equivalents of water with 
respect the complex). The experiments were run in triplicate. 
2.3.2. Effect of compounds on growth of E. coli 
To each well of a 96-well plate (Sarstedt), 100 μL of fresh nutrient broth medium were added. A 
serial dilution of each compound was performed on the plate to give a concentration range of 
(150–0.59 μM). Cells suspension (100 μL) of E. coli (1 × 106 cells/mL) was added to each well and 
the plates were incubated at 37 °C for 24 h. The experiments were carried out in duplicate. The 
OD570nm of the cultures was determined using a microplate reader (Bio-Tek, Synergy HT) and 
all growth was expressed as a percentage of that in the control. The MIC50 and MIC80 (Minimum 
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Inhibition Concentration) are defined as the lowest concentration to inhibit growth by 50% and 
80%, respectively.  Since being the first time, the antibacterial activity was studied in these 
complexes, the most common and representative bacteria of each family were selected: 
Escherichia coli is gran negative, Staphylococcus aureus is gran positive, Staphylococcus aureus 
(MRSA) is methicillin resistant, yeast Candida albicans as a fungi representative. 
 
2.3.3. Computational method 
Structures and energetics were modelled by Density Functional Theory (DFT) at the 
wB97XD/lanL2DZ level of theory, which performs well in prediction of reaction geometries and 
energies.40 Implicit solvation was introduced with the Solvation Model based on Density (SMD) 
parametrization software Gaussian09 with explicit solvents of acetonitrile, DMSO and water. The 
ground state geometry of each compound was optimized in implicit solvent by including the 
effect of the polarizable continuum in the self-consistent field procedure. The explicit micro-
solvation model was built by adding five water molecules to the reactant complex, the whole 
hydrated complex was then re-optimized in implicit DMSO. The initial positions of the water 
molecules were selected manually by maximizing the possibility of forming hydrogen bonds 
between water molecules and the compounds in order to find the most stable structures of 
reactants and products upon optimizations. The initial models were optimized, for the analysis 
we retained the three lower energy structures of the reactants (Figure 2.10) and the lowest 
energy structure of the hydrated products (Figure 2.11). Frequency calculations allowed the 
characterization of the potential energy surface and the evaluation of the thermochemistry of 
the involved compounds. All computations were performed with Gaussian16. 
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2.3.4. Synthesis and Characterization  
 
                                           
201. 201 was obtained following the procedure of Albeck with a slight modification. TeCl4 (0.27 
g, 1 mmol) was refluxed with dry ethylene glycol (0.15 g, 2.6 mmol) in dry CH3CN (2ml) for 4 h at 
80oC.  A white crystalline solid precipitated out after cooling the reaction at r.t and it was 
recovered by filtration, washed with cold CH3CN and Et2O and dried under vacuum. Yield (46%). 
Elem. Anal. %C (7.70), %H (2.58), %N (4.49); found C (7.85) H (2.38) N (4.79) 
1H NMR (DMSO-d6): δ 4.37(s, 4H, (CH2)2): 7.20(t,4H, NH4) 
13C NMR (DMSO-d6): δ 67.44 (CH2)2 
125Te (DMSO-d6): δ = 1680 
IR cm-1 (ATR): 3189: 2932: 1398: 1334: 1217: 1106: 1017: 991: 865 cm-1 
 
 
202. TeCl4 (0.28 g, 1 mmol) was refluxed with dry 1,2 Propanediol (0.18 g, 2.3 mmol) in dry 
CH3CN (2ml) for 4 h at 80oC.  A white crystalline solid precipitated out after cooling the reaction 
at r.t.  and it was recovered by filtration, washed with cold CH3CN and Et2O and dried under 
vacuum. Yield (52%).  
Elem. Anal. %C (11.05), %H (3.09), %N (4.30); found C (10.83) H (3.21) N (4.49). 
1H NMR (DMSO-d6): δ = 1.21 (d, 3H, CH3): 3.65 (t, CH), 4.33 (t, 1H, CH), 4.84 (t, 1H, CH), 7.33 (t, 
4H, NH4) 
13C NMR (DMSO-d6): δ = 18.70 (CH3), 72.72 (CH2), 74.31 (CH) 
125Te (DMSO-d6): δ = 1692. 
(-) ESI mass: peak at m/z 307.83 corresponding to [C3H6Cl3O2Te]-. 
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IR cm-1 (ATR): 3158: 2937: 1397: 1336: 1235: 1122: 1068: 979: 837 cm-1 
 
                                    
203. TeCl4 (0.28 g, 1 mmol) was refluxed with 1,2 Butanediol (0.21 g, 2.4 mmol) in dry CH3CN 
(2ml) for 24 h at 80oC.  A white crystalline solid precipitated after addition of diethyl ether at r.t. 
and it was recovered by filtration, washed with cold CH3CN and Et2O and dried under vacuum. 
Yield (72%). 
Elem. Anal. %C (14.13), %H (3.56), %N (4.12); found C (14.52) H (3.69) N (4.49). 
1H NMR (DMSO-d6): δ 0.93 (t, 3H, CH3), 1.56 (m, 2H, CH2), 3.71 (t, 1H, CH), 4.17 (t, 1H, CH), 4.82 
(s, 1H, CH), 7.33 (t, 4H, NH4). 
13C NMR (DMSO-d6): δ 10.01 (CH3), 26.19 (CH2), 71.10 (CH2), 79.55 (CH). 
125Te (DMSO-d6): δ = 1692. 
(-) ESI mass: peak at m/z 321.85 corresponding to [C4H8Cl3O2Te]-. 
IR cm-1 (ATR): 3160: 2965: 1402: 1332: 1118: 1081: 1029: 975:  960: 934: 858: 774 cm-1 
 
 
204. TeCl4 (0.36 g, 1.2 mol) was refluxed with 1,2 Pentanediol (0.32 g, 3 mmol) in dry CH3CN (2ml) 
for 120 h at 80oC.  A white crystalline solid precipitated after addition of diethyl ether at r.t. and 
recovered by filtration, washed with cold CH3CN and Et2O and dried under vacuum. Yield (61%). 
Elem. Anal. %C (16.96), %H (3.96), %N (3.99); found C (16.85), H (4.09), N (4.29). 
1H NMR (DMSO-d6): δ = 0.89 (t, 3H, CH3), 1.40 (m, 2H, CH2), 1.51 (m, 2H, CH2), 3.69 (t, 1H, CH), 
4.24 (t, 1H, CH), 4.81 (s, 1H, CH), 7.26 (t, 4H, NH4). 
13C NMR (DMSO-d6): δ = 14.08 (CH3), 18.57 (CH2), 35.28 (CH2), 71.37(CH2), 78.03 (CH). 
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125Te (DMSO-d6): δ = 1690. 
(-) ESI mass: peak at m/z 335.87 corresponding to [C5H10Cl3O2Te]-. 
IR cm-1 (ATR): 3145: 3046: 2961: 1403: 1083: 994: 964: 892: 838: 678 cm-1 
 
 
 
205. TeCl4 (0.44 g, 1.5 mmol) was refluxed with 1,2 Hexanediol (0.35 g, 3 mmol) in dry CH3CN 
(2ml) for 120 h at 80oC.  A white crystalline solid precipitated after addition of diethyl ether at 
r.t. and it was recovered by filtration, washed with cold CH3CN and Et2O and dried under vacuum. 
Yield (56%). 
Elem. Anal. %C (19.58), %H (4.38), %N (3.80); found C (19.40), H (4.08), N (4.05). 
1H NMR (DMSO-d6): δ = 0.87 (d, 3H, CH3): 1.30 (m, 2H, CH2), 1.39 (m, 2H, CH2), 1.54 (m, 2H, CH2) 
3.70 (t,1H, CH), 4.23 (t,1H, CH), 4.85 (t,1H, CH), 7.23 (t, 4H, NH4). 
13C NMR (DMSO-d6): δ = 13.88 (CH3), 22.23 (CH2), 27.44 (CH2), 32.81 (CH2), 71.44 (CH2), 78 (CH). 
125Te (DMSO-d6): δ = 1692. 
IR cm-1 (ATR): 3154: 2958: 1401: 1084: 1051: 999: 963: 858: 782: 680 cm-1 
 
 
206. TeCl4 (1.09 g, 3.7 mmol) was refluxed with 1,2 Octanediol (1.35 g, 9.2 mmol) in dry CH3CN 
(15ml) for 120 h at 80oC.  A white crystalline solid precipitated after addition of diethyl ether at 
r.t. and it was recovered by filtration, washed with cold CH3CN and Et2O and dried under vacuum. 
Yield (53%) 
Elem. Anal. %C (24.25), %H (5.09), %N (3.54); found C (24.40), H (5.32), N (3.25). 
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1H NMR (DMSO-d6): δ = 0.85 (t, 3H, CH3), 1.25 (m, 6H, (CH2)3), 1.38 (m, 2H, CH2), 1.51 (m, 2H, 
CH2), 3.68 (t, 1H, CH), 4.21 (t, 1H, CH), 4.79 (t, 1H, CH), 7.29 (t, 4H, NH4). 
13C NMR (DMSO-d6): δ = 13.93 (CH3), 22.01 (CH2), 25.22 (CH2), 28.79 (CH2), 31.18 (CH2), 33.20 
(CH2) 71.33 (CH2), 78.25(CH). 
125Te (DMSO-d6): δ = 1687. 
IR cm-1 (ATR): 3151: 2929: 1402: 1073: 1012: 961: 885: 849: 789: 722: 688 cm-1 
 
 
207. TeCl4 (0.97 g, 3.3 mol) was refluxed with 3-Chloro-1,2 Propanediol (0.7 g, 8.2 mmol) in dry 
CH3CN (15ml) for 120 h at 80oC. A yellow/white solid precipitated after addition of diethyl ether 
at r.t. and it was recovered by filtration, washed with cold CH3CN and Et2O and dried under 
vacuum. Yield 30%. 
Elem. Anal. %C (10.00), %H (2.52), %N (3.89); found C (10.13), H (2.28), N (3.64). 
1H NMR (DMSO-d6): δ = 3.70 (m, 2H, CH2), 4.03 (t, 1H, CH), 4.51 (t, 1H, CH), 4.72 (t, 1H, CH), 7.29 
(t, 4H, NH4). 
13C NMR (DMSO-d6): δ = 45.81 (CH2), 68.28 (CH2), 78.15 (CH). 
125Te (DMSO-d6): δ = 1673. 
 
 
208. TeCl4 (0.97 g, 3.3 mol) was refluxed with 1-phenyl-1,2-ethandiol (1.14 g, 8.2 mmol) in dry 
CH3CN (15ml) for 120 h at 80oC. The solution turned a slight red colour at first and after 1 hr a 
green solution was formed.  After 4 h, diethyl ether was added to but no solid precipitated.  A 
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black/green oil was obtained after drying the solution under vacuum but from the NMR it was a 
mixture of several different species.  
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2.3.5. Figures 
 
 
 
Figure 2.14. NMR spectra of 201; A: 1H, B: 13C and C: 125 Te NMR in DMSO-d6 
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Figure 2.15. NMR spectra of 202; A: 1H, B: 13C and C: 125 Te NMR in DMSO-d6 
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Figure 2.16. NMR spectra of 203; A: 1H, B: 13C and C: 125 Te NMR in DMSO-d6 
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Figure 2.17. NMR spectra of 204; A: 1H, B: 13C and C: 125 Te NMR in DMSO-d6 
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Figure 2.18. NMR spectra of 205; A: 1H, B: 13C and C: 125 Te NMR in DMSO-d6 
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Figure 2.19. NMR spectra of 206; A: 1H, B: 13C and C: 125 Te NMR in DMSO-d6 
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Figure 2.20. NMR spectra of 207; A: 1H, B: 13C and C: 125 Te NMR in DMSO-d6 
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Figure 2.21. ESI-Mass spectra (-) of (top to bottom) of 202, 203 and 204. 
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Figure 2.22.  IR spectrum of compound 201 
 
Figure 2.23. IR spectrum of compound 202 
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Figure 2.24. IR spectrum of compound 203 
 
Figure 2.25. IR spectrum of compound 204 
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Figure 2.26. IR spectrum of compound 205 
 
Figure 2.27. IR spectrum of compound 206 
 
 
Figure 2.28. A: 13C NMR of 201 (0.5 mM in DMSO-d6), B: 201 + 10uL D2O (10 equivalents), C: 201 + 20uL 
D2O (20 equivalents), D: 201 + 30uL D2O (30 equivalents) and E: free ligand. 
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Figure 2.29. A: 13C NMR of 202 (0.5 mM in DMSO-d6), B: 202 + 10uL D2O (10 equivalents), C: 202 + 20uL 
D2O (20 equivalents), D: 202 + 30uL D2O (30 equivalents) and E: free ligand. 
 
Figure 2.30. A: 13C NMR of 204 (0.5 mM in DMSO-d6), B: 204 + 10uL D2O (10 equivalents), C: 204 + 20uL 
D2O (20 equivalents), D: 204 + 30uL D2O (30 equivalents) and E: free ligand. 
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Figure 2.31. A: 13C NMR of 205 (0.5 mM in DMSO-d6), B: 205 + 10uL D2O (10 equivalents), C: 205 + 20uL 
D2O (20 equivalents), D: 205 + 30uL D2O (30 equivalents) and E: free ligand. 
 
 
Figure 2.32. A: 13C NMR of 206 (0.5 mM in DMSO-d6), B: 206 + 10uL D2O (10 equivalents), C: 206 + 20uL 
D2O (20 equivalents), D: 206 + 30uL D2O (30 equivalents) and E: free ligand. 
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Figure 2.33. A: 13C NMR of 207 (0.5 mM in DMSO-d6), B: 207 + 10uL D2O (10 equivalents), C: 207 + 20uL 
D2O (20 equivalents), D: 207 + 30uL D2O (30 equivalents) and E: free ligand. 
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3.1 Introduction 
 
In the previous chapter, the tellurium compound AS101 and its derivatives were studied, where 
only one of the two vicinal carbons of the diol was substituted with an alkyl chain. All these 
complexes possessed one secondary and one tertiary carbon in the main chain of the diol ligand. 
In this chapter, we decided to explore if the same class of compounds could be formed 
substituting both the diol vicinal carbons.  The following diol ligands were explored whose 
structure are shown in Figure 3.1 (in brackets the corresponding Te-compounds): 
● pinacol, 1,1,2,2 tetramethyl-1,2 ethanediol (301-309); 
●  1,1,2,2 tetraphenyl 1,2-ethanediol (310); 
● catechol (311); 
● hexafluoro 2,3 bis(trifluoromethyl) 2,3 butanediol (312); 
● 2,3-butandiol (313). 
 
Figure 3.1. Structures of the diol ligands studied in this chapter. From left to right:  pinacol, 1,1,2,2 
tetramethyl-1,2 ethanediol; 1,1,2,2 tetraphenyl 1,2-ethanediol; hexafluoro 2,3-bis(trifluoromethyl) 2,3 
butanediol; cathecol; 2,3-butandiol. 
 
These Tellurium(IV) compounds, were obtained by reacting the corresponding diol with TeCl4 in 
nitrile solutions, in a similar way as the reaction performed in chapter 2.  Compounds can be 
extracted as solids, by filtration after the solution was concentrated by rotary evaporation or by 
the addition of Et2O, as oil or can be purified by column chromatography. Complexes 301 and 
302 were also synthesised in microwave similar to those of the AS101 analogues (chapter 2), 
thus reducing the reaction time from several hours to 40 mins. 
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Unfortunately, only with pinacol,  1,1,2,2 tetramethyl-1,2 ethanediol, it has been possible to 
isolate and completely characterise the tellurium compounds, while with all the other ligands 
the nature of the final products are still not clear.  
3.2 Results and Discussion 
 
3.2.1. Synthesis and Characterisation 
The first reaction that was attempted was between pinacol and TeCl4 in acetonitrile. The reaction 
was conducted following the procedure of the AS-101 derivatives described in chapter 2. By 
addition of Et2O to the acetonitrile solution cooled at r.t after several hours of reflux, a nice 
yellow powder was isolated (See Experimental Part 3.5). Surprisingly, the product obtained was 
completely different from the analogues of AS-101. From multinuclear NMR studies (1H, 13C and 
125Te), IR spectroscopy and X-Ray structure analyses, it was possible to identify the new 
compound 301 as a salt where TeCl62- is the anion and an oxazoline derivative (formed by 
reaction between pinacol and acetonitrile) is the cation (Scheme 3.1). 
 
Scheme 3.1. Synthetic pathway for the synthesis of 301. 
Unfortunately, even if X-Ray analyses, NMR and IR spectra were in agreement with the structure 
proposed, the elemental analyses did not match with the final formula of the salt, 
C16H32Cl6N2O2Te.  Furthermore, it was evident that the reaction in Scheme 3.1 was not 
stoichiometric; together with 301, another species was formed, [TeCl2(OH)2] that precipitated 
together with the salt after addition of Et2O (Scheme 3.2). 
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Scheme 3.2. Stoichiometric synthetic pathway for the synthesis of 301. 
The Elemental Analyses did match somewhat with the mixture of the two compounds (El. Anal. 
% Calcd. For C16H34Cl8N2O4Te2 C: 22.42, H: 4.00; N: 3.27; found C: 22.02, H: 4.32; N: 3.57). From 
NMR and IR spectra the presence of the second species [TeCl2(OH)2] in the mixture was not 
easy to identify. Nevertheless, the two species can be separated by dissolving the mixture in a 
minimum amount of MeOH and by removal of [TeCl2(OH)2], that crashed out by addition of 
water, while 301 remains in solution. The Elemental Analyses of the purified 301 was found with 
the formula (El. Anal. % Calcd. For C16H32Cl6N2O2Te C: 30.76, H: 5.16; N: 4.48; found C: 30.25, H: 
5.62; N: 4.87). We decided to investigate if the same class of compounds could have been formed 
modifying the nitrile nature; analogues have been isolated and characterized with X-Ray 
structure analysis with benzonitrile (302) and 4-trifluoromethyl-benzonitrile (303), as shown in 
Scheme 3.3. 
 
Scheme 3.3. Stoichiometric synthetic pathway for the synthesis of 302 (top) and 303 (bottom). 
The reaction was explored also with different nitriles, including 3-trifluoro-methylbenzonitrile 
(304), fluoroacetonitrile (305), 2,3Dimethoxybenzonitrile (306), trichloroacetonitrile (307), 
cyclohexene-nitrile (308) and naphto-nitrile (309). Only with fluoroacetonitrile (305) and 2,3 
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Dimethoxybenzonitrile (306) analogues compounds were isolated; the reaction using the other 
nitriles did not produce clear and pure compounds (See Experimental Part 3.5).  
Compounds 301, 302 and 303 were characterised by X-Ray crystallography.  
 
 
Figure 3.2. X-Ray structure of 301. Left: the full salt; right the TMO tetramethyloxozolium cation 
(molecules of DMF removed for clarity). 
301. The crystals were obtained by diffusion of Et2O into a DMF solution of 3.1. The asymmetric 
unit of the dimethylformamide-solvated salt [CH3-TMO]2[TeCl6]·2DMF (301) encloses a CH3-TMO 
cation (TMO = TetraMethylOxazolium), a DMF solvate molecule (not shown) and half 
hexachlorotelurate anion. The Te(IV) ion is located at the crystallographic inversion center (origin 
of the unit cell), and displays the expected bond distances (Te1–Cl1, 2.5431(4) Å; Te1–Cl2, 
2.5380(4) Å; Te1–Cl3, 2.5494(4) Å) and angles (maximal deviation from right angle: Cl2–Te1–Cl3, 
91.102(13)°). The molecular ring of the pentamethyloxazolium cation (Table 1) exhibits an 
expected distortion, as the C3–N4–C5 angle (111.31(12)°) widens upon protonation. In addition, 
the O1–C2–C3–N4 torsion angle was found to be 23.32(12)°. This is probably due to the steric 
accommodation of the four methyl substituents at the endocyclic C–C bond. The N1H site is 
involved in hydrogen bonding with the oxygen atom of a neighboring DMF molecule (2.6872(16) 
Å). Crystal data for Compound 301: [C22H46Cl6N4O4Te], orthorhombic, Pbca, a = 15.5390(14) Å, b 
= 12.2853(11) Å, c = 17.8374(16) Å, Z = 4, Mr = 770.93, V = 3405.2(5) Å3, Dcalcd = 1.504 g cm–3, 
λ(Mo Kα) = 0.71073 Å, T = 100 K, µ = 1.377 mm–1, 74355 reflections collected, 4631 unique (Rint 
= 0.0454), 3948 observed, R1(Fo) = 0.0208 [I > 2σ(I)], wR2(Fo2) = 0.0550 (all data), GOF = 1.051. 
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Figure 3.3. X-Ray structure of 303. Left: the full salt; right the TMO tetramethyloxozolium cation. 
303. Crystals were obtained by diffusion of Et2O into a 4-trifluoromethyl-benzonitrile solution. 
The compound [CF3Ph-TMO]2[TeCl6] (303) crystallizes in the monoclinic C2/c space group, and 
the unit cell encloses half TeCl62– anion, and an oxazolium derivative cation, namely, 4,4,5,5-
tetramethyl-2-(p-trifluoromethyl-phenyl)oxazolium. Two Te–Cl distances of the anion differ 
significantly from those observed in 301 (Te1–Cl1, 2.4557(4) Å; Te1–Cl2, 2.5341(4) Å; Te1–Cl3, 
2.6432(4) Å), whereas bond angles remain unaltered (Table 1). As in the case of 301, cation 303 
exhibits a wide C3–N4–C5 angle (110.72(11)°) and a pronounced O1–C2–C3–N4 twist angle 
(26.64(11)°). The intramolecular hydrogen bonding pattern could be responsible for the 
hexafluorotelurate anion distortion, a the N4 site H-binds a Cl3 ligand (N4(H)···Cl3, 3.2495(12) 
Å). Thus, each TeCl62– anion is connected to two CF3Ph-TMO+ cations. Crystal data for Compound 
303: [C28H34Cl6F6N2O2Te], monoclinic, C2/c, a = 19.5893(16) Å, b = 7.4413(6) Å, c = 23.8477(19) 
Å, β = 90.8384(12)°, Z = 4, Mr = 884.87, V = 3475.9(5) Å3, Dcalcd = 1.691 g cm–3, λ(Mo Kα) = 0.71073 
Å, T = 100 K, µ = 1.379 mm–1, 19515 reflections collected, 4829 unique (Rint = 0.0188), 4499 
observed, R1(Fo) = 0.0198 [I > 2σ(I)], wR2(Fo2) = 0.0487 (all data), GOF = 1.036. 
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Table 1. Endocyclic ring angles [°] and distances [Å] of cations in 301 and 303. 
 301 303 
O1–C2 1.5111(17) 1.4938(16) 
C2–C3 1.5577(19) 1.5548(18) 
C3–N4 1.4817(17) 1.4938(16) 
N4–C5 1.2887(19) 1.2953(17) 
O1–C5 1.3191(17) 1.3138(16) 
C5–O1–C2 107.36(10) 107.31(10) 
O1–C2–C3 101.41(10) 101.38(9) 
N4–C3–C2 99.64(11) 98.66(9) 
C5–N4–C3 111.31(12) 110.72(11) 
N4–C5–O1 114.03(13) 113.77(12) 
 
By diffusion of Et2O into a benzonitrile solution of 302, crystals were obtained but the X-ray 
structure is not of good quality, even if the nature of the compounds is clearly identified (Figure 
3.4).  
 
Figure 3.4. X-Ray structure of 302. 
All the compounds 301-313 were characterised by elemental analysis, IR spectroscopy, 1H, 13C, 
125Te and 19F NMR (all the spectra are reported at the end of this chapter in the section 3.5). All 
the compounds show a unique 125Te NMR peak in DMSO-d6 around 1525 ppm, the region of 
TeCl62- species. In the IR spectra is clearly visible the stretching of the C=N between 1618-
1671 cm−1.  When comparing IR spectra of that of starting ligand pinacol and compounds 301-
303, the stretching at 3439cm-1 (OH) disappeared in the IR of 301–303 and new peaks are seen 
at 1500-1656 cm-1 (C=N); 2979 cm-1 (CH3).  Compounds containing CF3 group show the 
characteristic CF3 symmetrical stretching at 1100 cm-1 and symmetrical CF3 deformation at 700 
cm-1 in the IR spectra.1 Compounds 301, 302, 303, 305 and 306 are very stable in deuterated 
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DMSO. The 1H NMR spectrum of the free pinacol ligand shows two signals corresponding to the 
two OH groups (3.52 ppm, broad singlet) and to the methyl groups at 1.06 ppm (singlet) and the 
13C NMR spectrum shows the equivalent CH3 groups at 25.8 ppm (singlet) and the two vicinal 
carbons at 74.4 ppm (singlet). In 301, the methyl groups and the vicinal carbons are no more 
equivalent; the 13C NMR spectrum of 301 shows six peaks corresponding to the CH3 group of 
acetonitrile at 14 ppm, the CH3 groups of pinacol at 22.4 and 22.6 ppm, the vicinal carbons at 
65.5 and 97.0 ppm and the quaternary carbon of CH3CN at 173.0 ppm (all the assignments were 
done via 2D-COSY/TOCSY/HMBC/HSQC spectra). The 1H NMR for compound 301 shows three 
peaks, two corresponding to the two sets of CH3 of the pinacol at 1.36 and 1.49 ppm and the CH3 
of the acetonitrile at 2.34 ppm.  The NH protonated is visible as a broad singlet at 6.7 ppm. The 
125Te NMR shows one single peak at 1523 ppm corresponding to the TeCl62- anion. Analogues 
spectra are obtained for 302, 303, 305 and 306. 
1H NMR of 302 shows five peaks,  two singlets of the two sets of CH3 of the pinacol at 1.47 and 
1.60 ppm and three multiplets associated to the aromatic protons of the benzene ring at 7.67, 
7.86 and 8.10 ppm (integrals 2:2:1). The 13C NMR spectrum for 302 shows 9 signals: 22.3 and 
22.7 (two sets of CH3 pinacol),   66.5 and 97.2 ppm for the two vicinal carbons,   167.0 ppm 
(quaternary carbon of the benzonitrile) and four peaks of the aromatic benzene ring at 129. 7, 
129.5, 121.2 and 129.5 ppm. The 125Te NMR shows a peak at 1524ppm. 
1H NMR of 303 was similar to that of 301 and 302 in that it shows the two sets of methyl groups 
of pinacol (no more equivalent) at 1.46 and 1.58 ppm and  two multiplets at 8.06 and 8.28 ppm 
of the aromatic protons.   13C NMR of 303 is a little more complex due to the coupling between 
the carbons and the 19F of the CF3 group. The two sets of methyl groups of pinacol appear at 22.4 
and 22.9 ppm; the vicinal carbons are at 67.0 and 96.5 ppm and the quaternary carbon of the 
nitrile at 165 ppm. All the carbons of the benzene ring are coupling with different constants with 
the 19F of the CF3 and show three different quartets at 126.0, 130.0 and 136.6 ppm. The carbon 
of the CF3 appear as a quartet at 124 ppm. The 125Te NMR shows again a broad peak at 1521 
ppm, very close to the other 125Te peaks. Finally, 19F NMR shows one peak at -62 ppm for the CF3 
group. 1H NMR spectrum of 305 with fluoro-acetonitrile, shows similar pattern as the previous 
three compounds with the two sets of pinacol methyl groups at 1.27 and 1.51 ppm and one 
doublet at 5.52 ppm corresponding to the CH2 protons (coupling with 19F). The 13C NMR spectrum 
for 305 show peaks at 22.5, 22.6, 66.4, 77.21, 76.0 and 169.7 ppm.  The 125Te NMR shows a peak 
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at 1523 and the 19F NMR shows a peak at -20.4 ppm for the CF3 group. The last compound that 
formed analogues Te(IV) species is with the 2,3-dimethoxy benzonitrile, 306. The 1H NMR 
spectrum shows the same pattern for the peaks of the methyl groups of pinacol at 1.27 and 1.40 
ppm, two multiplets between 7-7.25 ppm of the aromatic protons and one broad peak at 3.85 
of the methoxy groups. 13C NMR spectrum of 306 shows 13 peaks, the first two are assign again 
to those of the methyl groups of pinacol at 22.9 and 24.2 ppm, two peaks to the vicinal carbons 
at 69.5 and 88.5 ppm, one peak at 160 ppm of the quaternary carbon of the nitrile, six aromatic 
carbons at 153.2, 148.4, 124.4, 122.4, 115.2 and 110.1 ppm and two methoxy carbons at 61.4 
and 56.3 ppm. The 125Te NMR shows a peak at 1523 ppm. As mentioned before, unfortunately, 
with all the other nitriles (304, 307, 308 and 309) or replacing pinacol with other diols (310, 311, 
312, and 313) no clear compounds were obtained and characterised. Nevertheless, the NMR 
spectra did not show the same pattern of the previous species and the integrals did not match 
with the hypothetical structure. Theoretical calculations will be conducted in order to 
understand the mechanism of formations of these species and to understand the effect of the 
steric/electronic properties of the diol/nitrile in the formation of these species. All the spectra 
are reported in the experimental part 3.5.  
 
3.2.2. Stability in aqueous conditions. 
 
As mentioned before, the nature of these new class of compounds was quite surprising. The 
cation was a protonated oxazoline, a cyclic five member ring with an endo-imino ether (-N=C-O-
) group. The chemistry of oxazoline has been extensively studied and reviewed.1 Several ways 
are known for the syntheses of oxazoline, including cyclisation of 2-amino-alcohol2, reaction 
between acyl-chlorides and amino-alcohol, the Appeal reaction and reaction between nitriles 
and amino-alcohol catalysed by ZnCl2 (Pinner reaction)3. Oxazolines have been synthesised since 
the early 19th century and since their discovery, their chemistry has been investigated 
intensively.3-8  
It must also be noted  that the same reaction did not happen if TeCl4 was replaced by other Lewis 
Acids, such as AlCl3, ZnCl2 or MgCl2. Reacting TeCl4 with an excess of pinacol (10 equivalents) in 
acetonitrile, afforded the same compound 301. This could suggest that TeCl4 could act as a 
catalyst and a catalytic mechanism is proposed in Figure 3.5. This is only a hypothesis and will be 
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confirmed and combined by theoretical calculations. Another important advantage with respect 
the common zinc-catalysed reactions, is that the formation of these oxazoline derivatives also 
happens at r.t. without refluxing conditions.  
 
Figure 3.5. Catalytic mechanism proposed for the syntheses of Te-catalysed oxazolines. 
 
Milne showed that [TeCl6]2- in water is in equilibrium with different Te(IV)-hydroxo-chloride 
species (Figure 3.5), including [Te(OH)Cl4]- and [Te(OH)2Cl2].9, 10 125Te NMR shows a broad peak 
around 1250 ppm demonstrating a rapid exchange of all the Te species in solution. 301, 302 and 
303 compounds were selected to study their stability in aqueous environment. The compounds 
were accurately weighted in a NMR tube, dissolved in DMSO-d6 and aliquots of D2O were added 
were added (10, 20, 30, 40 and 50 equivalents, see Experimental). The 1H, 13C, 125Te and 19F NMR 
were collected after each addition and after one week after each addition, in order to allow the 
systems to reach the equilibrium. All the compounds were not stable after addition of water and 
they decomposed forming new species with a very similar NMR pattern compared to the parent 
species, with all the peaks shifted up-field.  
An accurate integration of the 1H-NMR peaks, allowed the determination of the stability 
performance of 301, 302 and 303 (Figure 3.6 for compound 301, see Experimental Part 3.5 for 
302 and 303). 
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Figure 3.6. 1H (left), 13C (centre) and 125Te (right) NMR of: A) 301 (0.5 mM in DMSO-d6); B) 301 + 10 μL D2O 
(10 eq.); C) 301 + 20 μL D2O (20 eq.); D) 301 + 30 μL D2O (30 eq.); E) 301 + 40 μL D2O (40 eq.); F) 301 + 50 
μL D2O (50 eq.); F) 301 + 50 μL D2O (50 eq.) after 3 weeks. 
 
 
 
Figure 3.7 and Table 3.2 show the plot of the stability data for the three compounds analysed, 
301, 302 and 303. 303 containing a CF3 group is the least stable, decomposing of almost 85% 
after addition of 50 equivalents of D2O. The acetonitrile derivative, 301, is the most stable, with 
a decomposition of only 50 % after addition of 50 equivalents.  
 
 
Figure 3.7. Decomposition of compounds 301, 302 and 303 with addition of water. Left, marked line 
representation; right, 2D column representation. 10 equiv D2O, 20 equiv D2O, 30 equiv D2O, 40 equiv D2O, 
50 equiv D20, 50 equiv D2O after 3 weeks. 
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Table 3.2. Percentage of decomposition of compounds 301, 302 and 303 after addition of 10-50 
equivalents of D2O. 
equivalents of D2O  301 302 303 
0 0 0 0 
10 0 21 171 
20 41 51 462 
30 121 101 692 
40 232 192 823 
50 272 212 843 
50 after 3 weeks 503 563 853 
 
Makino and co-workers11 reported that oxazolines, in the presence of acidic solution and 
nucleophiles (H-X), decomposes as shown in Figure 3.811. We speculate that the product that is 
forming upon addition of D2O could be a similar species, due to the presence of an acidic 
environment (Figure 3.5, confirmed also by litmus paper). The reason for the different stability 
performance, will be investigated by theoretical calculations, but we can hypothesise that the 
presence of electro-withdrawing groups, such as CF3, will increase the polarisation of C and make 
it more amenable to nucleophilic attack of X- (Figure 3.8). 
 
Figure 3.8. Mechanism proposed for the decomposition of the oxazoline cations in 301, 302 and 
303. 
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3.3 Experimental 
 
3.3.1. Material and methods 
 
TeCl4, all the diol ligands and all the nitriles have been purchased from Sigma-Aldrich or TCI 
Europe. All solvents were used without further purification except for CH3CN which was kept dry 
over molecular sieves under inert atmosphere. All NMR spectra were recorded on a Bruker 
Advance spectrometer with the probe at 293 K, operating at 500 MHz for the 1H, at 125 MHz for 
the 13C, 470 MHz for 19F and at 158 MHz for the 125Te nucleus, respectively. Spectra were 
recorded in DMSO-d6 using Me4Si as the internal standard for 1H and 13C while diphenyl 
ditelluride was used as external reference for 125Te. All chemical shifts δ are reported in ppm. 
Infrared (IR) spectra were recorded in the region 4000–400 cm−1 on a Perkin Elmer ATR 
(Attenuated Total Reflectance) precisely spectrum 100 FT/IR spectrometer. Elemental analysis 
(carbon, hydrogen and nitrogen) were performed with a PerkinElmer 2400 series II analyser. The 
stability of the complexes has been evaluated following the decomposition reaction by 1H, 13C 
and 125Te NMR. Each compound was accurately weighted and dissolved in 400 μL of DMSO-d6 to 
obtain 125 mM solution (0.05 mmoles). 10 μL of D2O were added in three consecutive aliquots 
and the NMR spectra were recorded 1 h after each addition (each addition corresponds to 
10 equivalents of water with respect the complex). The experiments were run in triplicate. 
 
3.3.2. Synthesis and Characterization  
 
 301. TeCl4 (1g, 3.4mmol) was refluxed with Pinacol C6H14O2 (0.8g, 6.77mmol) in 8ml of dry 
acetonitrile for 4hrs at 80oC. After 4hrs a yellow solution remained.  A light yellow crystalline 
solid precipitated after addition of diethyl ether at r.t. and it was recovered by filtration, washed 
with cold CH3CN and Et2O and dried under vacuum. The powder was re-dissolved in 3 mL of 
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MeOH and 25 mL of water were added. A white solid formed, [Te(OH)2Cl2] that was removed by 
filtration. The filtrate was dried, washed with MeOH and Et2O and dried in vacuum, obtaining a 
yellow solid.   
 Yield 76%. M.W: 624.3g/mol 
Elem. Anal. %C (30.75), %H (5.13), %N (4.49); found C (30.25), H (5.62), N (4.87. 
1H NMR (DMSO-d6): δ = 1.36 (s, 6H, CH3), 1.49 (s, 6H, (CH3), 2.34 (s, 3H, CH3) 
13C NMR (DMSO-d6): δ = 14.05 (CH3), 22.36 (CH3, CH3), 22.62 (CH3, CH3), 65.50 (C-N),                97.81 
(C-O), 173.8 (O-C=N)  
125Te (DMSO-d6): δ = 1523. 
IR cm-1 (ATR): 3213, 2979, 1656, 1503, 1468, 1401, 1379, 1247, 1168, 1120, 1078, 1013, 955, 
907, 801cm-1 
 
                                              
302. TeCl4 (0.5357g, 1.81mmol) was refluxed with Pinacol C6H14O2 (0.2136g, 1.81mmol) in 8ml of 
benzonitrile for 4hrs at 80oC. After 4hrs a yellow solution remained.  A light green crystalline 
solid precipitated after addition of diethyl ether at r.t. and it was recovered by filtration, washed 
with cold Et2O and dried under vacuum. The powder was re-dissolved in 3 mL of MeOH and 25 
mL of water were added. A white solid formed, [Te(OH)2Cl2] that was removed by filtration. The 
filtrate was dried, washed with MeOH and Et2O and dried in vacuum, obtaining a yellow/green 
solid. Yield 49%. M.W: 748.3g/mol 
Elem. Anal. %C (41.7), %H (4.81), %N (3.70); found C (40.1), H (4.67), N (3.4). 
1H NMR (DMSO-d6): δ = 1.47 (s, 6H, CH3), 1.60 (s, 6H, (CH3), 7.67 (d, 2H, CH2), 7.86 (d, 1H, CH), 
8.10 (d, 2H, CH2) 
13C NMR (DMSO-d6): δ = 22.33 (CH3, CH3), 22.75 (CH3, CH3), 22.62, 66.52 (C-N), 97.21 (C-O), 167.25 
(O-C=N), 121.18, 129.47, 129.65, 136.16  
125Te (DMSO-d6): δ = 1525. 
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IR cm-1 (ATR): 3142, 1618, 1459, 1377, 1356, 1268, 1167, 1167, 1143, 1095, 1041, 775,   670cm-
1 
 
 
303. TeCl4 (0.4129g, 1.39mmol) was refluxed with Pinacol C6H14O2 (0.1646g, 1.39mmol) and 4-
trifluoro-methylbenzonitrile (1.12g, 6.6mmol) for 4hrs at 80oC. The nitrile started off as solid but 
when 40oC turned to liquid.  After 30mins the solution turned from yellow to dark brown 
solution. After 4hrs reaction stopped and flask cooled on ice bath.  A green brown crystalline 
solid precipitated after addition of diethyl ether at r.t. and it was recovered by filtration, washed 
with cold Et2O and dried under vacuum. The powder was re-dissolved in 3 mL of MeOH and 25 
mL of water were added. A white solid formed, [Te(OH)2Cl2] that was removed by filtration. The 
filtrate was dried, washed with MeOH and Et2O and dried in vacuum, obtaining a green solid. 
Yield 38%. M.W: 884.9g/mol 
Elem. Anal. %C (38.01), %H (3.87), %N (3.17); found C (37.7), H (3.51), N (2.90). 
1H NMR (DMSO-d6): δ = 1.46 (s, 6H, CH3), 1.58 (s, 6H, (CH3), 8.02 (d, 2H, CH2), 8.28 (d, 2H, CH2) 
13C NMR (DMSO-d6): δ = 22.48 (2CH3), 22.94 (2CH3), 67.41 (quat), 95.5 (quat), 165 (-C=N), 120 
(CF3), 122 (CH), 124 (CH), 126 (CH), 130(quat), 134 (quat), 134.27 (CH).  
125Te (DMSO-d6): δ = 1521. 
19F NMR (DMSO-d6): δ = -61.96 
IR cm-1 (ATR): 3142, 1618, 1459, 1377, 1356, 1268, 1167, 1167, 1143, 1095, 1041, 775, 670cm-1 
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304. TeCl4 (0.8801g, 2.9mmol) was refluxed with Pinacol C6H14O2 (0.3427g, 2.9mmol) and 3-
trifluoro-methylbenzonitrile (2.562g, 15mmol) for 4hrs at 80oC. After 60mins the solution turned 
from yellow to dark brown solution. After 4hrs reaction stopped and flask cooled on ice bath.  A 
green brown crystalline solid precipitated after addition of diethyl ether at r.t. and it was 
recovered by filtration, washed with cold Et2O and dried under vacuum. Yield 24%. 
Elem. Anal. %C (24.25), %H (5.09), %N (3.54); found C (24.40), H (5.32), N (3.25). 
1H NMR (DMSO-d6): δ = 1.38 (s, 6H, CH3), 1.52 (s, 6H, (CH3), 8.19 (d, 2H, CH2), 7.85 (d, 2H, CH2), 
8.19, 8.26, 8.34 
13C NMR (DMSO-d6): δ = 22.51 (2CH3), 23.04 (2CH3), 67.47 (quat), 96.45 (quat), 164.89 (-C=N), 112 
(CF3), 117 (CH), 122 (CH), 124 (CH), 131 (quat), 133 (quat), 136 (CH). 
125Te (DMSO-d6): δ = 1525. 
19F NMR (DMSO-d6): δ = -61.46 
IR cm-1 (ATR): 3181, 2229, 1644, 1598, 1510, 1439, 1327, 1120, 919, 805, 734, 692, 659 cm-1 
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305. TeCl4 (0.666g, 2.25mmol) was refluxed with Pinacol C6H14O2 (0.2659g, 2.25mmol) and 
fluoroacetonitrile (1g, 17mmol) for 4hrs at 80oC. After 10mins the solution turned from yellow 
to dark brown solution. After 4hrs reaction stopped and flask cooled on ice bath.  A dark brown 
crystalline solid precipitated after addition of diethyl ether at r.t. and it was recovered by 
filtration, washed with cold Et2O and dried under vacuum. Yield 23%. M.W: 893.24g/mol 
Elem. Anal. %C (21.51), %H (3.61), %N (3.14); found C (22.21), H (4.03), N (4.06). 
1H NMR (DMSO-d6): δ = 1.37 (s, 6H, CH3), 1.51 (s, 6H, CH3), 5.47 (s, 1H, CH), 5.56 (s, 1H, CH) 
13C NMR (DMSO-d6): δ = 22.49 (2CH3), 22.64 (2CH3), 66.40 (quat), 76 (quat), 164.70 (-C=N), 
77.21 (CH) 
125Te (DMSO-d6): δ = 1523. 
19F NMR (DMSO-d6): δ = -20.18 
IR cm-1 (ATR): 3154, 1671, 1513, 1379, 1243, 1162, 1073, 951, 881. 782 cm-1 
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306. TeCl4 (0.76g, 2.56mmol) was refluxed with Pinacol C6H14O2 (0.3025g, 2.56mmol) and 2,3 
Dimethoxybenzonitrile (0.8476g, 5.2mmol) for 4hrs at 120oC. After 10mins the solution turned 
from yellow to black solution. After 4hrs reaction stopped and flask cooled on ice bath. Dried for 
1hr on rotavap and a dark crude solution remained. Product was removed through column 
chromatography 100:1 DCM to methanol. A dark brown oil was extracted.  
1H NMR (DMSO-d6): δ = 1.27 (s, 6H, CH3), 1.40 (s, 6H, CH3), 3.85 (s, 6H, CH3), 7.00 (m, 2H, CH), 
7.26(t, 1H CH) 
13C NMR (DMSO-d6): δ = 22.94 (2CH3), 24.20 (2CH3), 56.27 (OCH3), 61.41 (OCH3), 69.49 (quat), 
88.51 (quat), 110 (CH), 115 (CH), 122 (CH), 124 (quat), 149 (quat), 153 (quat), 161 (-C=N) 
125Te (DMSO-d6): δ = 1523. 
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307. TeCl4 (0.8963g, 3mmol) was refluxed with Pinacol C6H14O2 (0.3545g, 3mmol) and 
trichloroacetonitrile (4.32g, 30mmol) for 4hrs at 80oC. After 30mins the solution turned from 
yellow to dark green solution. After 4hrs reaction stopped and flask cooled on ice bath. Dried 
for 1hr on rotavap and a dark crude solution remained. A dark green oil was extracted.  
1H NMR (DMSO-d6): δ = 0.98 (s, 6H, CH3), 1.09 (s, 6H, CH3), 2.00 
13C NMR (DMSO-d6): δ = 24.88 (CH3, CH3), 26.13 (CH3, CH3), 56.27, 92.9 (C-N), 113.45, 128.90, 
162.95) 
125Te (DMSO-d6): δ = 1526. 
 
308. TeCl4 (0.695g, 2.34mmol) was refluxed with Pinacol C6H14O2 (0.277g, 2.34mmol) and 1-
cyclohexeneacetonitrile (2.63g, 8.25mmol) for 8hrs at 130oC.  After 15mins the solution turns 
dark brown in colour.  After 8hrs reaction stopped and solution allowed to cool to r.t.  Attempted 
to dry on rotavap to reduce solvent but would not reduce.  Diethyl ether added to precipitate 
solid a grey fine powder achieved but analysing solid showed no product produced. 
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309.  TeCl4 (0.44g, 1.48mmol) was refluxed with Pinacol C6H14O2 (0.35g, 3mmol) and 1-
napthonitrile (0.44g, 3mmol) for 6hrs at 80oC.  After 5mins the solution changed colour from 
yellow to a dark solution.  After 6hrs the reaction was stopped and allowed to cool to r.t.  
Attempts to try recover a solid by evaporation of solvent and addition of diethyl ether and 
petroleum ether failed to recover solid.  A dark oil had formed which could not be purified. 
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310. TeCl4 (0.1513g, 0.5mmol) was refluxed with 1,1,2,2 tetraphenyl 1,2 ethanediol C26H22O2 
(0.1832g, 0.5mmol) and dry acetonitrile (10ml) for 4hrs at 80oC.  The solution stayed yellow for 
the entire reaction. After 4hrs reaction stopped and flask cooled on ice bath. Dried for 1hr on 
rotavap and a yellow solid was extracted.  
1H NMR (DMSO-d6): δ = 1.76 (s, 3H, CH3),  7.16 (6H), 7.30 (1H), 7.58 (2H) 
13C NMR (DMSO-d6): δ = 22.46 (CH3), 70.60 (quat), 126 (quat), 127 (CH), 130 (CH), 132 (CH), 136 
(quat), 143 (quat), 171 (-C=N), 197 (CH) 
125Te (DMSO-d6): δ = 1525. 
                                            
311. TeCl4 (0.5893g, 2mmol) was refluxed with Catechol C6H8O2 (0.2202g, 2mmol) and 
dry acetonitrile (5ml) for 4hrs at 80oC.  The solution started off yellow in colour but 
after 1.5hrs changed to a red solution. After 4hrs reaction stopped and flask cooled on 
ice bath. Dried for 1hr on rotavap and a dark brown oil formed.  
1H NMR (DMSO-d6): δ = 1.18 (s, 3H, CH3), 6.69 (t, 4H) 
13C NMR (DMSO-d6): δ = 8.67, 45.65, 113.9, 115.67, 119.79, 145.25, 149.16 
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125Te (DMSO-d6): δ = 1524. 
 
 
312. TeCl4 (0.7651g, 2.6mmol) was refluxed with hexafluoro 2,3 bis(trifluoromethyl) 2,3 
butanediol [(CF3)2C(OH)2] (0.8686g, 2.6mmol) and dry acetonitrile (5ml) for 16hrs at 80oC.  The 
solution started off yellow in colour for entire reaction. After 16hrs reaction stopped and flask 
cooled on ice bath. Dried for 1hr on rotavap and a dark brown oil formed.  
1H NMR (DMSO-d6): δ = 1.23 (s, 3H, CH3), 7.26  
13C NMR (DMSO-d6): δ = 25.55, 62.86, 74.83, 77.16, 80.23 
125Te (DMSO-d6): δ = 1525.65. 
19F NMR (DMSO-d6): δ = -70.51 
 
 
313. TeCl4 (1.239g, 4.2mmol) was refluxed with 2,3 butanediol C4H10O2 (0.2202g, 4.2mmol) and 
dry acetonitrile (10ml) for 12hrs at 80oC.  The solution started off yellow in colour but after 
1.5hrs changed to a red solution. After 12hrs reaction stopped and flask cooled on ice bath. 
Dried for 1hr on rotavap and a dark yellow oil formed. When oil analysed using NMR found 
that reaction did not occur. 
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3.3.3. Figures 
 
 
 
 
Figure 3.09.  NMR spectra of compound 301. (A) 1H NMR, (B) 13NMR and (C) 125Te NMR 
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Figure 3.10. NMR spectra of compound 302. (A) 1H NMR, (B) 13NMR and (C) 125Te NMR 
Te(IV)-pinacol salts compounds                                                                                                                   Chapter 3 
 
105 
 
 
 
 
Figure 3.11. NMR spectra of compound 303. (A) 1H NMR, (B) 13NMR and (C) 125Te NMR 
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Figure 3.12. NMR spectra of compound 304. (A) 1H NMR, (B) 13NMR, (C) 125Te NMR and (D) 19F NMR 
Te(IV)-pinacol salts compounds                                                                                                                   Chapter 3 
 
107 
 
 
 
 
 
Figure 3.13. NMR spectra of compound 305. (A) 1H NMR, (B) 13NMR, (C) 125Te NMR and (D) 19F NMR 
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Figure 3.14. NMR spectra of compound 306. (A) 1H NMR, (B) 13NMR and (C) 125Te NMR 
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Figure 3.15. NMR spectra of compound 307. (A) 1H NMR, (B) 13NMR and (C) 125Te NMR 
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Figure 3.16. NMR spectra of compound 310. (A) 1H NMR, (B) 13NMR and (C) 125Te NMR 
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Figure 3.17. NMR spectra of compound 311. (A) 1H NMR, (B) 13NMR and (C) 125Te NMR 
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Figure 3.18. NMR spectra of compound 312. (A) 1H NMR, (B) 13NMR, (C) 125Te NMR and (D) 19F NMR in 
DMSO-d6 
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Figure 3.19.  IR spectrum of free Pinacol 
 
Figure 3.20. IR spectrum of compound 301 
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Figure 3.21. IR spectrum of compound 302 
 
 
Figure 3.22. IR spectrum of compound 303 
 
 
Figure 3.23. IR spectrum of compound 304 
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Figure 3.24. IR spectrum of compound 305 
 
 
 
 
 
Figure 3.25. IR spectrum of compound 310 
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Figure 3.26. A: 1H NMR of 301 (0.5 mM in DMSO-d6), B: 301 + 10uL D2O (10 equivalents), C: 301 + 20uL 
D2O (20 equivalents),  D: 301 + 30uL D2O (30 equivalents), E: 301 + 40uL D2O (40 equivalents) and F: 301 + 
50uL D2O (50 equivalents) 
 
Figure 3.27. A: 13C NMR of 301 (0.5 mM in DMSO-d6), B: 301 + 10uL D2O (10 equivalents), C: 301 + 20uL 
D2O (20 equivalents), D: 301 + 30uL D2O (30 equivalents), E: 301 + 40uL D2O (40 equivalents) and F: 301 + 
50uL D2O (50 equivalents) 
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Figure 3.28. A: 1H NMR of 302 (0.5 mM in DMSO-d6), B: 302 + 10uL D2O (10 equivalents), C: 302 + 20uL 
D2O (20 equivalents), D: 302 + 30uL D2O (30 equivalents), E: 302 + 40uL D2O (40 equivalents) and F: 302 + 
50uL D2O (50 equivalents) 
 
Figure 3.29. A 13C NMR of 302 (0.5 mM in DMSO-d6), B: 302 + 10uL D2O (10 equivalents), C: 302 + 20uL 
D2O (20 equivalents), D: 302 + 30uL D2O (30 equivalents), E: 302 + 40uL D2O (40 equivalents) and F: 302 + 
50uL D2O (50 equivalents) 
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Figure 3.30. A: 1H NMR of 303 (0.5 mM in DMSO-d6), B: 303 + 10uL D2O (10 equivalents), C: 303 + 20uL 
D2O (20 equivalents), D: 303 + 30uL D2O (30 equivalents), E: 303 + 40uL D2O (40 equivalents) and F: 303 + 
50uL D2O (50 equivalents) 
 
Figure 3.31. A: 13C NMR of 303 (0.5 mM in DMSO-d6), B: 303 + 10uL D2O (10 equivalents), C: 303 + 20uL 
D2O (20 equivalents), D: 303 + 30uL D2O (30 equivalents), E: 303 + 40uL D2O (40 equivalents) and F: 303 + 
50uL D2O (50 equivalents) 
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A series of new Te(IV) complexes were synthesized with the aim to discover new stable Te(IV) 
species with high antimicrobial and anticancer activity. Despite the large success of metal-based 
complexes in medicinal chemistry for the cure of several diseases, in particular as antimicrobial 
and anticancer agents (i.e. platinum, ruthenium, gold…), very few examples of Tellurium-based 
drugs are reported.  In particular, only two Tellurium compounds entered in clinical trials as 
antitumor compounds, named AS-101 and SAS. Both these species are based on a Te(IV)-scaffold 
with O-donor ligands that are displaced in physiological condition by hydrolysis. The novel 
compounds synthesized can be divided in two different families: 
1) Compounds 201-208 (described in chapter 2) where the ligands used are substituted 
1,2-diols with only one vicinal carbon functionalized; 
2) Compounds 301-313 (described in chapter 3) where the ligands used are substituted 
1,2-diols with both vicinal carbons functionalized. 
The stability of the first series of compounds with regard hydrolysis, has been evaluated 
combining experiment data (via multinuclear 1H, 13C, 19F, 125Te-NMR) with theoretical 
calculations. A correlation between the alkyl chain length of the ligand and the aqueous stability 
was observed, with longer chains, that are more steric encumbered and more lipophilic, showing 
increased stability for the corresponding Te(IV) compounds. Theoretical investigation 
demonstrated that longer chains prevents the approach of water molecules in proximity of the 
Te(IV) centre with consequently decrease in the hydrolytic rate. This trend was confirmed using 
two different theoretical methods, the implicit solvation and the explicit solvation approach. The 
antimicrobial activity of some of these compounds was tested with promising high activity 
against Gran negative E. Coli (MIC50 values in the low micromolar concentration). Due to the 
biological conditions, the species responsible of the antimicrobial activity was identified as the 
hydrolysed product [TeOCl3]-, which is further reduced to elemental Tellurium (black precipitate 
observed at the bottom of the plates). The second series of compounds (chapter 3) were 
obtained using identical conditions as for the first series but modifying both the vicinal carbons 
in the 1,2-diol chain. With pinacol, also known as (1,1,2,2 
tetramethyl-1,2 ethanediol), completely different products were obtained. These species were 
salts where the anion is [TeCl6]2- and the cation is an oxazoline derivative. These oxazolines 
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ligands are formed by the reaction between one activated molecule of acetonitrile (used as 
solvent) and pinacol, in the presence of TeCl4. Analogues species are isolated also using different 
nitriles, in particular benzonitrile and 4-trifluoromethyl-benzonitrile. TeCl4 could act as a catalyst 
in the formation of these species and the reaction also works at r.t. This is a great advantage 
with respect the common procedures for the syntheses ox oxazolines, that usually require 
stronger conditions. 
These new compounds have been characterized using several spectroscopic techniques 
(multinuclear NMR, IR, Mass, Elemental Analyses) and some of them were also characterized by 
X-ray structure. The stability in aqueous conditions was studied experimentally via accurate 
multinuclear NMR analyses. These species decompose upon addition of 10 or more equivalents 
of H2O and the kinetics of decomposition depends on the electric properties of the starting nitrile 
molecule. 4-trifluoromethyl-benzonitrile derivative decomposed faster and this is probably due 
to the electro-withdrawing properties of the CF3 group that enhance the nucleophilic attack on 
the oxazoline ring.  Theoretical investigation will be an important tool to understand the 
mechanism of formation of this second series of compounds. Due to note that these species are 
not forming with other bis-susbstituted diols (i.e. 1,1,2,2 tetraphenyl 1,2-ethanediol, catechol, 
hexafluoro 2,3 bis(trifluoromethyl) 2,3 butanediol, 2,3-butandiol) or with other nitriles (i.e. 
trichloroacetonitrile, cyclohexene-nitrile, naphto-nitrile). A theoretical approach will be also 
used in order to understand why these class of compounds can be isolated only with pinacol 
derivatives while with other bis-substituted 1,2-diol ligands or with other nitriles, analogues 
species are not obtained.  Once the mechanism of formation and the mechanism of hydrolytic 
cleavage will be elucidated, anticancer activity and proteomics studies will allow to clarify the 
still not clear mechanism of action of Te(IV) compounds. 
In particular, the following aspects will be considered regarding the anticancer activity: 
- Study of the drug uptake 
- Cytotoxycity against a panel of human cancer cell lines and non-cancer cell lines; 
- ROS productions; 
- Drugs uptake and correlation with the lipophilicity; 
- Mechanism of drug uptake (active or passive transport); 
- Flow cytometry; 
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- Evaluation of the selectivity for cancer against non-cancer cells; 
- Proteomics. 
Antimicrobial activity will be studied using the second series of compounds and the results 
compared with those obtained for the first series. This is a pioneer study on the biological role 
of tellurium and, due to the unclear role and mechanism of action of Te(IV)-compounds, there 
are several opportunities and chances to open a completely new field in medicinal chemistry, by 
developing novel stable Te(IV)-based drugs. 
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A B S T R A C T
Inorganic Te(IV) compounds are important cysteine protease inhibitors and antimicrobial agents; AS-101 [ammonium trichloro (dioxoethylene-O,O′)tellurate] is the
first compound of a family with formula NH4[C2H4Cl3O2Te], where a Te(IV) centre is bound to a chelate ethylene glycol, and showed several protective therapeutic
applications. This compound is lacking in stability performance and is subjected to hydrolysis reaction with displacement of the diol ligand. In this paper, we report
the stability trend of a series of analogues complexes of AS-101 with generic formula NH4[(RC2H3O2)Cl3Te], where R is an alkyl group with different chain length and
different electronic properties, in order to find a correlation between structure and stability in aqueous-physiological conditions. The stability was studied in solution
via multinuclear NMR spectroscopy (1H, 13C, 125Te) and computationally at the Density Functional Theory level with an explicit micro solvation model. The
combined experimental and theoretical work highlights the essential role of the solvating environment and provides mechanistic insights into the complex de-
composition reaction. Antimicrobial activity of the compounds was assessed against different bacterial strains.
1. Introduction
Tellurium is a metalloid element with several available oxidation
states going from −2 to +6 [1]. Tellurides of formula M2Te are com-
pounds formed by Te(-II) and noble elements such as Au or Ag that are
highly unstable and in the presence of oxygen's are oxidised to tellurite
[Te(IV)O3]2− [2]. The biological properties of tellurium are poorly
characterized, but it is known that some bacteria and fungi are able to
uptake Te as amino acids, replacing the Sulfur atom and forming
Tellurium-cysteine and Tellurium methionine [3,4]. The oxidation state
+4 is the most stable and interesting from biological application, with
multiple complexes of organo‑tellurium(IV), containing a direct TeeC
bond, reported. These complexes are stable in aqueous solution and
seem to have a promising and potential role in protease inhibition and
integrin inactivation [5–14]. Besides these families of organo‑tellurium
complexes, Albeck and co-worker's ultimately developed two “in-
organic” tellurate Te(IV) compounds, named AS-101 [ammonium tri-
chloro (dioxoethylene-O,O′)tellurate] and SAS [octa-O-bis-(R,R)-tarta-
rate ditellurane] whose structure is depicted in Fig. 1. These complexes
are effective inhibitors of cysteine protease and showed several pro-
tective therapeutic applications and in vivo, preclinical and clinical
studies have been conducted [15–26].
Te(IV) compounds can inhibit integrin functions such as adhesion,
migration and metalloproteinase secretion mediation in B16F10 murine
melanoma cells. AS-101 in particular, can stimulate the proliferation of
normal lymphoid cells producing lymphokines that are regulators of
lymphopoiesis and myelopoiesis [17]. AS-101 also showed strong an-
tibacterial activity in particular on Gram-negative bacterium En-
terobacter cloacae [27]. Recently, Albeck and Cunha, reported that AS-
101 is not stable in physiological conditions and is subjected to hy-
drolysis where the diol ligand is displaced with the formation of [Te(IV)
OCl3]−, which is likely the bioactive species in biological investigation
[28,29]. Due to the promising activity of AS-101 in term of anticancer
and immune-modulating properties, we sought to design, synthesise
and characterize a series of AS-101 analogues with different ligands, in
order to investigate their stability properties in aqueous environment
and ultimately found a tellurate Te(IV) complex stable enough to per-
form biological studies in physiological conditions.
The ethylene glycol of AS-101 has been substituted with a series of
diols with increasing alkyl chain length and electron withdrawing
groups, producing eight novel Te(IV) complexes with formula
NH4[(RC2H3O2)Cl3Te] (where R=H (1); CH3 (2); CH2CH3 (3);
CH2CH2CH3 (4); CH2CH2CH2CH3 (5); CH2CH2CH2CH2CH2CH3 (6);
CH2Cl (7); Ph. (8)). The aqueous stability has been evaluated using 1H,
13C and 125Te NMR and theoretical studies allowed an understanding of
the molecular basis of the observed trend. The modelling of the reaction
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mechanism suggests that a longer alkyl chain substituent enhances the
stability of the complex by interfering with the formation of water
clusters necessary for mediating the proton transfer steps involved in
the hydrolysis of the TeeO bonds. The antimicrobial activity was
evaluated in vitro on Escherichia coli and other bacteria strains.
2. Experimental
2.1. Material and methods
TeCl4 and all the diol ligands have been purchased from Sigma-
Aldrich or TCI Europe. All solvents were used without further pur-
ification except for CH3CN which was kept dry over molecular sieves
under inert atmosphere. All NMR spectra were recorded on a Bruker
Advance spectrometer with the probe at 293 K, operating at 500MHz
for the 1H, at 125MHz for the 13C and at 158MHz for the 125Te nucleus,
respectively. Spectra were recorded in DMSO‑d6 using Me4Si as the
internal standard for 1H and 13C while diphenyl ditelluride was used as
external reference for 125Te. All chemical shifts δ are reported in ppm.
FT-IR spectra were recorded (compounds 1 and 3) from either CsI disks
(solid samples) or KRS-5 thallium bromoiodide cells (neat liquid sam-
ples) at room temperature on a Perkin Elmer Frontier FT-IR/FIR spec-
trophotometer in the range 4000–600 cm−1 (32 scans, resolution
4 cm−1) and in the range 600–200 cm−1 (32 scans, resolution 2 cm−1).
Data processing was carried out using OMNIC version 5.1 (Nicolet
Instrument Corporation). For all the other compounds Infrared (IR)
spectra were recorded in the region 4000–400 cm−1 on a Perkin Elmer
ATR (Attenuated Total Reflectance) precisely spectrum 100 FT/IR
spectrometer. Elemental analysis (carbon, hydrogen and nitrogen) were
performed with a PerkinElmer 2400 series II analyser. ESI (Electro
Spray Ionisation) mass spectra were recorded in negative mode with a
Waters LCT Premier XE Spectrometer. The stability of the complexes
has been evaluated following the decomposition reaction by 1H, 13C
and 125Te NMR. Each compound was accurately weighted and dissolved
in 400 μL of DMSO‑d6 to obtain 125mM solution (0.05mmoles). 10 μL
of D2O were added in three consecutive aliquots and the NMR spectra
were recorded 1 h after each addition (each addition corresponds to
10 equivalents of water with respect the complex). The experiments
were run in triplicate.
2.1.1. Effect of compounds on growth of E. coli
To each well of a 96-well plate (Sarstedt), 100 μL of fresh nutrient
broth medium were added. A serial dilution of each compound was
performed on the plate to give a concentration range of (150–0.59 μM).
Cells suspension (100 μL) of E. coli (1× 106 cells/mL) was added to
each well and the plates were incubated at 37 °C for 24 h. The experi-
ments were carried out in duplicate. The OD570nm of the cultures was
determined using a microplate reader (Bio-Tek, Synergy HT) and all
growth was expressed as a percentage of that in the control. The MIC50
and MIC80 (Minimum Inhibition Concentration) are defined as the
lowest concentration to inhibit growth by 50% and 80%, respectively.
2.1.2. Computational method
Structures and energetics were modelled by Density Functional
Theory (DFT) at the wB97XD/lanL2DZ level of theory, which performs
well in prediction of reaction energies [30]. Implicit solvation was
introduced with the Solvation Model based on Density (SMD) para-
metrization. The ground state geometry of each compound was opti-
mized in implicit solvent by including the effect of the polarizable
continuum in the self-consistent field procedure. The explicit micro-
solvation model was built by adding five water molecules to the re-
actant complex, the whole hydrated complex was then reoptimized in
implicit DMSO. The initial positions of the water molecules were se-
lected by maximizing the possibility of forming hydrogen bonds be-
tween water molecules and the compounds in order to find the most
stable structures of reactants and products upon optimizations. The
initial hypotheses were optimized, for the analysis we retained the three
lower energy structures of the reactants (Fig. S19 in supplementary
material) and the lowest energy structure of the hydrated products (Fig.
S20). Frequency calculations allowed the characterization of the po-
tential energy surface and the evaluation of the thermochemistry of the
involved compounds. All computations were performed with Gaus-
sian16 [31].
3. Results and discussion
The series of eight complexes with formula NH4[(RC2H3O2)Cl3Te]
(where R=H (1); CH3 (2); CH2CH3 (3); CH2CH2CH3 (4);
CH2CH2CH2CH3 (5); CH2CH2CH2CH2CH2CH3 (6); CH2Cl (7); Ph. (8)),
analogues of AS-101, have been synthesised as described in the
Experimental part and in Scheme 1. Briefly, TeCl4 and the correspon-
dent diol were mixed in dry acetonitrile and the mixture was refluxed
for several hours. The solids were collected by filtration after con-
centration of the CH3CN solution or by addition of Et2O. The complexes
can be also synthesised by microwave as previously observed for AS-
101 [32] and the reaction mechanism involves four steps as described
by Sredni et al. [18]. The compounds were characterized by Elem.
Analysis, IR spectroscopy, Mass spectrometry, 1H, 13C and 125Te NMR
(all the spectra are reported in the Supporting Information Figs. S1–8).
All the complexes show a unique 125Te NMR peak in DMSO‑d6
around 1680 ppm, the typical region for these kind of species [33–34]
and in the IR spectra is clearly visible the stretching of the ammonium
counter cation at 3200 cm−1. A detailed IR study in the range
4000–200 cm−1 was done for compounds 1 and 3. Further insights into
the coordination sphere of tellurium can be obtained by comparison
with the IR spectra of the starting ethylene glycol, whose vibrations
have been fully assigned previously [35,36]. For instance, in the mid-IR
spectrum of compound 1 (Fig. S9) the bands associated with the –COH
moieties of the diol (ν(OH)=3400, δip(COH)= 1424,
δoop(COH)=644 cm−1) have disappeared, consistent with the co-
ordination of the deprotonated glycol to the Te(IV) centre. The CeO
stretching vibrations were detected at lower energy, in agreement with
values reported for analogous derivatives [18]. New bands were re-
corded at 3234 (νa(NH4+)) and 1408 (δa(NH4+)) cm−1 accounting for
the presence of the ammonium counterion [37]. In the far-IR region
(Fig. S10), the spectrum of compound 1 appears dramatically different
from that of ethylene glycol, the latter showing only one weak broad
band at 520 cm−1 assigned to the δ(CCO) [35]. In line with the results
reported by Albeck et al., [18] in the solid state the complex should
present a distorted square-pyramidal geometry in which the two oxygen
atoms of the deprotonated diol occupy the axial and one equatorial
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Fig. 1. Structure of the “inorganic” Te(IV) compounds AS-101 and SAS.
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Scheme 1. Synthesis of the complexes NH4[(RC2H3O2)Cl3Te], where R=H
(1); CH3 (2); CH2CH3 (3); CH2CH2CH3 (4); CH2CH2CH2CH3 (5);
CH2CH2CH2CH2CH2CH3 (6); CH2Cl (7); Ph. (8).
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positions. Accordingly, two tellurium‑oxygen stretching vibrations are
foreseeable, ν(Te-Oax) and ν(Te-Oeq), the former expected at higher
frequency [38]. For 1, Te-O vibrations were assigned to two new bands
recorded at 607 and 528 cm−1, respectively. Such assignments, to-
gether with the two intense bands observed at 467 and 406 cm−1 as-
signed to the overall deformation of the Te(O2C2)-ring, are fully con-
sistent with those reported for analogous derivatives [39]. According to
the very few relevant papers published to date, tellurium-chlorido de-
rivatives exhibit TeeCl stretching vibrations in the range
400–200 cm−1, such as 378/312 (TeCl4) [40], 220–250 ([TeCl6]2−)
[41,42], 286/263 (Ph2TeCl2) [43] and 271/221 ([Te(dioxoethylene-
O,O′)Cl3], Raman) cm−1 [44]. In the present study, two new intense
bands were recorded at 351 and 298 cm−1, which can be reasonably
assigned to the antisymmetric and symmetric stretching involving the
-TeCl3 moiety. The IR spectra of derivative 2 resemble closely those of
1. The same pattern of bands was observed in the far-IR region, whereas
in the 4000–600 cm−1 range the only minor differences would be at-
tributed to the new vibrations involving the CH3CH2CH- pendant, such
as those recorded at 3048 (ν(CH)), 2967/2872 (νa,s(CH3)), 1354
(δs(CH3)) and 776 (ρ(CH3)) cm−1 [44]. The complexes are very stable
in pure CH3CN or DMSO solution, but they decompose upon addition of
H2O, as previously described by Albeck and co-worker's [26]. The hy-
drolysis reaction releases the free diol with the formation of tri-
chloro‑tellurium (IV) oxide [TeOCl3]−, as depicted in Scheme 2.
The displacement of the ligand is followed by 1H, 13C and 125Te
NMR (Fig. 2 for 3): the signals of the coordinated and of the released
diols appear shifted in the NMR spectra, and this effect is particularly
remarked in the 13C NMR for the two carbons bound to the two donor
oxygen of the diols (Fig. 2 centre for compound 3 and Figs. S11–16).
After addition of 10, 20 and 30 equivalents of water, as explained in the
experimental part, the free diol is displaced with the formation of
NH4[TeOCl3], visible in the 125Te NMR at δ 1560 ppm (Fig. 2 right). To
confirm the nature of the decomposed product, 20mg of compound 3
were dissolved in 1mL of CH3CN and 5mL of H2O and, after 2 h, the
solution was dried under vacuum. The white solid obtained was washed
with cold CH3CN, H2O and diethyl ether and further dried under high
vacuum pressure. Mass spectrometry (Fig. S17, peak at (−) m/z 250.81
corresponding to [Cl3OTe]−) and Elem. Analysis confirm the nature of
the product as NH4[Cl3OTe] (Elem. Anal. %H (1.50), %N (5.23); found
H (1.91), N (5.04)).
Analysing the integrals of the released ligand vs the integrals of the
starting compound with respect the equivalents of water, it is possible
to estimate on the stability of the complexes.
The data show that there was an evident direct proportion between
the alkyl chain of the diol and the stability of the Te complexes; an
increase of the chain length corresponds to an increase of the stability,
with complex 6more stable than 5, 4, 3, 2 and 1 (Fig. 3). After addition
of 30 eq. of water, compound 1 is almost completely decomposed while
6 is more resistant (55% not decomposed). Complex 7 with a Cl electro-
withdrawing substituent is the least stable (it completely decomposes
upon addition of 20 eq. of H2O) while, unfortunately, it was not pos-
sible to evaluate the stability of complex 8, since it was not obtained
pure.
To gain a molecular understanding of the factors affecting the sta-
bility of the complexes we modelled at the quantum mechanical level
complex 1 and complex 5, representing the limiting case of short and
long alkyl-chain substituent, respectively, and complex 7 with the
chloro-methyl substituent. The optimized equilibrium geometries and
the analysis of the electronic structures in terms of atomic charges
[45,46] are reported in Fig. S18. Both atomic charges and structural
parameters of the Te centre are not significantly affected by the change
in the alkyl chain length nor by the chlorination of the substituent,
therefore it can be concluded that the origin of the slightly different
stability of the complexes does not stem from different strengths of the
TeeO bonds. As it also emerges from the stability studies, the solvating
environment plays a central role in establishing the equilibrium of the
decomposition reaction of the complexes. Computationally, there are
several approaches to treat solvation and we will use two of them in the
following to elucidate the energetics of the complex decomposition. In
the first approach (implicit solvation), the solvent is treated as a con-
tinuous, uniform dielectric medium characterized by its dielectric
constant Ɛ. The solute molecules are placed inside an empty cavity
within the dielectric medium and the interactions between solvent and
solute consists primarily of electrostatic interactions, that is the mutual
polarization of the solute and the solvent. We use the Solvation Model
based on Density (SMD) which was found to perform well for predicting
reaction energies in solution [47]. The reaction free energy, ΔGr, ob-
tained for the decomposition of the three complexes, 1, 5 and 7, by
considering the free energy of reactants and products implicitly sol-
vated in acetonitrile, DMSO and water are reported in Table 1, together
with the free energy of the same reactions in gas-phase. Positive values
of free energy of reactions reflect a stable complex which does not
undergo significant decomposition. From the analysis of the values of
the reaction free energy in implicit solvent we can draw two main
conclusions:
i) We do see consistent trend in how the relative gas-phase stability of
the three complexes is changed by solvation. Complex 5 is less prone
to decomposition than complex 1 in all the considered solvents and
complex 7 is the most destabilized by solvation. This can be un-
derstood by considering the solvation energies of the different spe-
cies involved in the reactions (see Table S1 in the Supporting
Information file) which show that the chloro-methyl substituted
glycol is considerably more stabilized by solvation than the corre-
sponding reactant complex. A word of caution must be given since
the calculated difference in the reaction free energies between
complex 1 and 5 (ΔΔGr of about 1–1.3 kcal/mol) is small and falls
within the error of the numerical method. On the other hand, such a
small difference is consistent with the experimental results which
report a decomposition of 0.8% for 1 and 0.4% for 5 in the case of
10 eq. of water (Fig. 3), corresponding to a difference in the reaction
free energies of the two complexes of about 2 kcal/mol.
ii) Because of the active involvement of water molecules in the de-
composition reaction, the implicit solvent calculations fail to predict
the spontaneous decomposition of the reactants in water. Indeed,
the use of a cavity model assumes that the solute electron density is
not changed by specific interactions with individual solvent mole-
cules and the reaction does not itself involve specific solvent mo-
lecules. The limitations resulting from these assumptions can be
addressed by including explicit solvent molecules inside the cavity.
We introduce an explicit micro-solvation environment by con-
sidering the complexes interacting with five water molecules (see
the reactants in Fig. 4). The solute and its hydration shell are then
considered solvated in DMSO with the implicit model to better re-
produce the experimental condition of the NMR experiments. Mul-
tiple equilibrium geometries of reactants and products were
Te
O
O Cl
Cl
Cl
R
Te
Cl
Cl
Cl
ONH4 +
DMSO/ H2O
OH
OH
R
NH4
Scheme 2. Hydrolysis reaction of Te(IV) complexes
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generated. We reported in Figs. S19 and S20 the structures of the
three lower lying energy structures of the hydrated complex and the
most stable structure of the products resulting from the decom-
position of Compound 1, 5 and 7. The reaction free energies are
reported in Table 1 for the different conformers of the reactants
R1–R3 (Fig. S20). We recover the spontaneous decomposition of the
complexes and an increased stability of the complex substituted
with the longer alkyl chain in good agreement with the experi-
mental findings. By defining the solvation contribution to the free
energy of reaction as the difference between the ΔGr calculated with
the explicit micro-solvation shell model and its gas-phase value we
find that these contributions are −27.3 kcal/mol, −18.2 kcal/mol
and −12.6 kcal/mol for complex 7, complex 1 and complex 5, re-
spectively. These results suggest that the trend in the stability of the
complexes increasing with the length of the alkyl chain results from
a less efficient hydration of the structure of the reactants relative to
the decomposition products.
Indeed, the mechanism of the decomposition reaction involves
multiple steps of proton transfer requiring the active involvement of
clusters of water molecules. Mechanistic insights into the decomposi-
tion reaction are shown in Fig. 4 and they were obtained by in-
vestigating the reaction path starting from the most stable structure of
the hydrated compound 1 (Reactant in Fig. 4). Structures with real
frequencies corresponds to minima of the potential energy surface, that
are equilibrium geometries of reactants, products and reaction inter-
mediates. Geometries of transition states correspond to a saddle point of
the Potential Energy Surface (PES) and are characterized by an ima-
ginary frequency for the mode identifying the reaction coordinate. The
mechanism of the decomposition reaction was assumed to consist of
two subsequent hydrolysis steps. We identify a transition state (TS1 in
Fig. 4) corresponding to the rupture of the first TeeO bond at a free
energy of +17.2 kcal/mol from the reactant complex. Breaking this
bond requires both a nucleophilic attack of a water molecule to the Te
centre together with a proton transfer from the water to the forming
glycol molecule. Following the intrinsic reaction coordinate
corresponding to the imaginary frequency of TS1 (see TS1.gif animation
in the Supporting Information) we find a reaction intermediate where a
-OH group is coordinated to the Te centre at an angle of about 120° from
the plane of the -TeCl3 moiety (H1a in Fig. 4). This structure can re-
arrange in other conformers (H1b and H1c in Fig. 4) where the most
stable (+1.7 kcal/mol from the reactant) is characterized by the -OH
group coordinated to Te in equatorial position. The hydrolysis of the
second TeeO bond to form the free glycol molecules again requires the
coordination of a second water molecule to the Te centre. This second
nucleophilic attack to the Te centre comes most probably from the side
opposite to the TeeO bond to break (see structure preH2 in Fig. 4). This
geometry implies that the water molecule attacking the Te centre
transfers its protons to other acceptors and the protonation of the glycol
is operated by a separate species (which might be a second water mo-
lecule or even a H3O+ ion). Most probably there are many possible
paths for these multiple proton transfer steps and the mechanistic de-
tails depends on the relative position of the hydrating water molecules.
The increasing of the decomposition ratio with the numbers of water
equivalents observed experimentally is readily explained by con-
sidering that clusters formed by a higher number of water molecules are
more efficient in mediating proton transfer steps trough the more ex-
tended H-bond network. From the intermediate structure where two
-OH groups are coordinated to the Te centre (H2 in Fig. 4) a further
proton transfer step leads to the formation of the trichloro Tellurium
(IV) oxide [OCl3Te]− (Products in Fig. 4) where one of the vertexes of
the square pyramid is occupied by a coordinated water molecule, at
least in solution. In the mass spectrum of the decomposed product, as
described before, the coordinated water molecule is not visible due to
the ESI conditions.
Since AS-101 and Te(IV) species showed antimicrobial activity
against Enterobacter cloacae and Pseudomonas aeruginosa, [27,48–51]
some of the complexes synthesised, (3, 4 and 5) together with the free
ligands, were selected and screened for antimicrobial activity against a
series of bacteria, including Escherichia coli, Staphylococcus aureus, me-
thicillin resistant Staphylococcus aureus (MRSA), Pseudomonas aerugi-
nosa, and the yeast Candida albicans.
Fig. 2. 1H (left), 13C (centre) and 125Te (right) NMR of: A) 3 (125mM in 400 μL DMSO‑d6); B) 3+10 μL D2O (10 eq.); C) 3+20 μL D2O (20 eq.); D) 3+30 μL D2O
(20 eq.); E) free 1,2-butandiol ligand.
Fig. 3. Decomposition of complexes 1–6 with addition of water. Left, marked line representation; right, 2D column representation.
K. D'Arcy, et al. Journal of Inorganic Biochemistry 198 (2019) 110719
4
The compounds showed interesting activity against the Gram ne-
gative bacterium E. coli (MIC50 values between 15 and 20 μM as re-
ported in Table 2) while they were less active or inactive against the
other bacteria and C. albicans. The free diol ligands that are displaced in
physiological conditions, have been analysed and they do not show any
activity. We conclude that the similar activity of the complexes is
probably due to the hydrolysed product [Cl3OTe]−. Interesting, a black
metallic, granular layer was visible in the assay medium of E. coli
treated plates and it is probably due to the reduction of the Te(IV) by
the bacteria, as already observed by Yang and co-workers (Fig. 5) [48].
4. Conclusions
A series of Te(IV) compounds of formula NH4[(RC2H3O2)Cl3Te]
where R is an alkyl chain with different length and electronic sub-
stituents, was synthesised and fully characterized and the stability in
aqueous media was investigated. Experimental observations are
matching with theoretical modelling using the explicit micro solvation
method, showing that all the complexes release the diol ligand upon
addition of water with hydrolytic cleavage of the TeeO bonds. The
decomposition reaction consists in two subsequent hydrolysis steps and
compounds with longer chains are more stable because the alkyl group
causes a less efficient hydration of the products and hinders the ne-
cessary proton transfer steps in the reaction. Nevertheless, even if there
is a correlation between alkyl chain length and stability, this latter is
not enough to claim that the promising antimicrobial activity observed,
in particular against Gram negative E. coli bacteria, is due to the starting
compounds. We can conclude instead, that these compounds act as
prodrugs by realising the hydrolysed product NH4[Cl3OTe], which acts
as the real bioactive species.
Table 1
Free energy of the decomposition reaction of compounds 1, 5 and 7. The table reports the gas-phase energy and the set of energies calculated with an implicit solvent
model of acetonitrile, dimethyl sulfoxide (DMSO) and water. The reaction considered in gas-phase and in implicit solvent was
[(RC2H3O2)Cl3Te]−+H2O= [RC2H3(OH)2]+ [Cl3OTe]− where reactants and products were considered as non-interacting molecules each species was solvated
separately. The second set of energies are calculated by explicit consideration of a hydration shell composed of five water molecules. The labels R1, R2 and R3 refers
to three different conformers of the hydrated reactant differing by the positions of the water molecules, see Figs. S19 and S20 for the structures of reactants and
products.
ΔGr (kcal/mol) Gas phase Implicit solvation Explicit microsolvation shell
Acetonitrile (ε=35.688) DMSO (ε=46.826) Water (ε=78.3553) R1 R2 R3
1 16.6 18.4 18.1 16.0 −1.6 −4.7 −5.4
5 17.5 19.4 19.4 17.2 4.9 −1.3 −2.8
7 23.3 18.2 17.9 15.9 −4.0 −11.5 −13.5
Fig. 4. Mechanistic insights into the decomposition reaction of 1 by considering an explicit micro-solvation shell formed by 5 molecules of water. The free energy of
the structures relative to the reactant complex is reported in parenthesis (in unit of kcal/mol). Geometries corresponding to black lines are minima of the potential
energy surface while TS1 is a transition state with an imaginary frequency of 131 cm−1 (see TS1.gif in SI). The vertical line in the middle of the picture divides the
hydrolysis of the fist TeeO bond from the hydrolysis of the second TeeO bond which leads to the formation of the free glycol.
Table 2
MIC50 and MIC80 values of the compounds 3–5 in E. coli.
Compound MIC50 (μM) MIC80 (μM)
3 19.8 ± 0.5 40.5 ± 0.6
4 18.4 ± 0.4 37.8 ± 0.7
5 17.1 ± 0.6 35.7 ± 0.8
K. D'Arcy, et al. Journal of Inorganic Biochemistry 198 (2019) 110719
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Supplementary data to this article can be found online at https://
doi.org/10.1016/j.jinorgbio.2019.110719.
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Fig. 5. Black precipitate observed at the bottom of the plate of E. coli treated
with 3.
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